Mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof by Sugaya, Kiminobu et al.
University of Central Florida 
STARS 
UCF Patents Technology Transfer 
12-22-2009 
Mammalian multipotent stem cells and compositions, methods of 
preparation and methods of administration thereof 
Kiminobu Sugaya 
Christopher Brannen 
University of Illinois 
Xiajing Dong 
University of Illinois 
Hojoong Kim 
University of Illinois 
Jose Pulido 
University of Illinois 
See next page for additional authors 
Find similar works at: https://stars.library.ucf.edu/patents 
University of Central Florida Libraries http://library.ucf.edu 
This Patent is brought to you for free and open access by the Technology Transfer at STARS. It has been accepted for 
inclusion in UCF Patents by an authorized administrator of STARS. For more information, please contact 
STARS@ucf.edu. 
Recommended Citation 
Sugaya, Kiminobu; Brannen, Christopher; Dong, Xiajing; Kim, Hojoong; Pulido, Jose; Qu, Tingyu; and 
Vaghani, Ankur, "Mammalian multipotent stem cells and compositions, methods of preparation and 
methods of administration thereof" (2009). UCF Patents. 770. 
https://stars.library.ucf.edu/patents/770 
Creator 
Kiminobu Sugaya, Christopher Brannen, Xiajing Dong, Hojoong Kim, Jose Pulido, Tingyu Qu, and Ankur 
Vaghani 
This patent is available at STARS: https://stars.library.ucf.edu/patents/770 
c12) United States Patent 
Sugaya et al. 
(54) MAMMALIAN MULTIPOTENT STEM CELLS 
AND COMPOSITIONS, METHODS OF 
PREPARATION AND METHODS OF 
ADMINISTRATION THEREOF 
(75) Inventors: Kiminobu Sugaya, Willow Springs, IL 
(US); Tingyu Qu, Chicago, IL (US); 
Ankur V. Vaghani, Chicago, IL (US); 
Christopher Brannen, Vancouver, WA 
(US); Hojoong M. Kim, Chicago, IL 
(US); Jose S. Pulido, Brookfield, WI 
(US); Xiajing Dong, Oak Park, IL (US) 
(73) Assignee: The Board of Trustees of the 
University of Illinois, Urbana, IL (US) 
( *) Notice: Subject to any disclaimer, the term ofthis 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 424 days. 
(21) Appl. No.: 10/345,126 
(22) Filed: Jan.14,2003 
(65) Prior Publication Data 
US 2003/0219898 Al Nov. 27, 2003 
Related U.S. Application Data 
(60) Provisional application No. 60/430,381, filed on Dec. 
2, 2002, provisional application No. 60/404,361, filed 
onAug. 19, 2002, provisional application No. 60/381, 
138, filed on May 8, 2002, provisional application No. 
60/376,257, filed on Apr. 29, 2002, provisional appli-
cation No. 60/357,783, filed on Feb. 19, 2002, provi-
sional application No. 60/348,473, filed on Jan. 14, 
2002. 
(51) Int. Cl. 
C12N 5100 (2006.01) 
C12N 5102 (2006.01) 
C12N 5106 (2006.01) 
C12N 5108 (2006.01) 
(52) U.S. Cl. ...................... 424/93.1; 435/377; 435/368; 
435/372; 435/373; 435/366; 435/325; 424/93.7 
(58) Field of Classification Search ....................... None 
See application file for complete search history. 
(56) References Cited 
U.S. PATENT DOCUMENTS 
4,959,368 A 9/1990 Awa ya 
5,104,650 A 4/1992 Ralph et al. 
5,411,883 A 5/1995 Boss et al. 
5,589,376 A 12/1996 Anderson et al. 
5,750,376 A 5/1998 Weiss et al. 
5,753,506 A 5/1998 Johe 
5,766,948 A 6/1998 Gage et al. 
5,851,832 A 12/1998 Weiss et al. 
5,925,567 A 7/1999 Kraus et al. 
5,968,829 A 10/1999 Carpenter 
5,976,523 A 1111999 Awayaet al. 
5,980,885 A 1111999 Weiss et al. 
6,013,521 A 112000 Gage et al. 
6,020,197 A 212000 Gage et al. 
I lllll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111 
US007635467B2 
(IO) Patent No.: US 7 ,635,467 B2 
(45) Date of Patent: Dec. 22, 2009 
6,040,180 A 3/2000 Johe 
6,090,624 A 712000 Greenwood et al. 
6,117,675 A 912000 van der Kooy et al. 
6,254,865 Bl 7/2001 Freed et al. 
6,284,245 Bl 9/2001 Edge 
6,306,575 Bl 10/2001 Thomas et al. 
6,368,854 B2 412002 Weiss et al. 
6,497,872 Bl 12/2002 Weiss et al. 
6,638,501 Bl 10/2003 Bjornson et al. 
6,670,397 Bl 12/2003 Baranowitz 
6,787,355 Bl* 912004 Miller et al. ................ 435/377 
6,808,702 B2 10/2004 Pasricha et al. 
6,824,973 B2 1112004 Tang et al. 
6,833,268 Bl 12/2004 Green et al. 
200110038836 Al 1112001 During et al. 
2002/0091133 Al 712002 Taylor 
2002/0142457 Al 10/2002 Umezawa et al. 
2002/0146821 Al 10/2002 Sanchez-Ramos et al. 
2002/0168350 Al 1112002 Brazelton et al. 
2002/0168765 Al 1112002 Prockop et al. 
2003/0053992 Al 3/2003 Rader et al. 
2003/0059868 Al 3/2003 Greenwood et al. 
2003/0118566 Al 6/2003 N eurnan et al. 
2003/0139410 Al 7/2003 Sugaya et al. 
2003/0148513 Al 8/2003 Sugaya et al. 
2003/0219898 Al 1112003 Sugaya et al. 
2004/0034049 Al 212004 Okawaet al. 
(Continued) 
FOREIGN PATENT DOCUMENTS 
EP 0 192 783 9/1986 
(Continued) 
OTHER PUBLICATIONS 
Coleman et al., Developmental Biology (1969), 19(6): 527-548 
Abstract, Caplus Accession No. 1969:420164.* 
(Continued) 
Primary Examiner-Daniel C Garnett 
(74) Attorney, Agent, or Firm-Timothy H. Van Dyke; 
Beusse Wolter Sanks Mora & Maire 
(57) ABSTRACT 
This invention provides methods for preparing novel mam-
malian multi potent stem cells (MSCs ), compositions thereof, 
and methods of preparing and administering the cells. 
46 Claims, 35 Drawing Sheets 
US 7,635,467 B2 
Page 2 
U.S. PATENT DOCUMENTS 
200410103448 Al 512004 Bjorklund 
2004/0106197 Al 6/2004 Okano et al. 
2005/0169897 Al 8/2005 Snyder et al. 
2005/0181503 Al 8/2005 Goldman et al. 
FOREIGN PATENT DOCUMENTS 
EP 0 305 184 3/1989 
EP 0 612 746 8/1994 
EP 0 648 495 4/1995 
JP 64-040483 2/1989 
JP 64-079183 3/1989 
JP 1-139572 6/1989 
JP 7-90002 4/1995 
JP 8-502172 3/1996 
JP 8-325268 12/1996 
JP 9-507747 8/1997 
JP 9-295946 1111997 
JP 9-328435 12/1997 
JP 10-504308 4/1998 
JP 2001-504123 3/2001 
JP 2001-526884 12/2001 
JP 2002-500624 112002 
JP 2002-502858 112002 
JP 2002-518990 712002 
WO WO 87/04928 8/1987 
WO WO 89/01938 3/1989 
WO WO 93/01275 111993 
WO WO 94/09119 4/1994 
WO WO 94/10292 5/1994 
WO WO 94/16718 8/1994 
WO WO 95/13364 5/1995 
WO PCT/CA95/00637 1111995 
WO WO 96/04789 2/1996 
WO W096/15226 5/1996 
WO WO 98/22127 5/1998 
WO WO 98/32457 7 /1998 
WO WO 99/11758 3/1999 
WO WO 99/32606 7 /1999 
WO WO 99/40107 8/1999 
WO WO 99/43286 9/1999 
WO PCT/US99/27613 1111999 
WO W000/29550 512000 
WO WO 00/69448 11/2000 
WO WO 01111011 2/2001 
WO WO 01134167 5/2001 
WO WO 01153461 Al 7/2001 
WO WO 01159072 8/2001 
WO WO 02/064748 8/2002 
WO PCT/US03/01254 7/2003 
WO W003/060085 A2 7/2003 
WO WO 2005/009359 A2 212005 
OTHER PUBLICATIONS 
Kidson et al., Experimental Cell Research, vol. 188, Issue 1, May 
1990, pp. 36-41, Abstract.* 
Kopenetal., Proc. Nat'l.Acad. Sci .. vol. 96, Issue 19, 10711-10716, 
Sep. 14, 1999.* 
Fukuyama et al., "A synthesized pyrimidine compound, MS-818, 
promotes walking function recovery from crush injury of the sciatic 
nerve through its indirect stimulation of Schwann cells" Restorative 
Neurology and Neuroscience 17 (2000) 9-16. 
Yoshikawa et al., "The Effect of MS-818, Newly Synthesized 
Pyrimidine Compound, on Fracture Repair" Kobe J Med. Sci. 
46:265-282 (Dec. 2000). 
Itoh et al., "The effect of neurotrophic pyrimidine heterocyclic com-
pounds, MS-818 and MS-430, on the regeneration of injured periph-
eral nerves" Restorative Neurology and Neuroscience 14:265-273 
(1999). 
Jiang et al., "The effect of MS-818, a pyrimidine compound, on the 
regeneration of peripheral nerve fibers of mice after a crush injury" 
Acta Neuropathol 90: 130-134 (1995). 
Yasuhara et al., "The Neurotrophic Pyrimidine Heterocyclic Com-
pound MS-818 Promotes the Angiogenesis Induced by Basic FGF" 
Int. J Clin. Pharm. Res. XV(5/6) 167-174 (1995). 
Koyama et al., "Neurotropic Pyrimidine Heterocyclic Compounds. 
II. Effects of Novel Neurotropic Pyrimidine Derivatives on 
Astrocytic Morphological Differentiation" Biol. Pharm. Bull. 20(2) 
138-141 (1997). 
Torigoe et al., "A newly synthesized neurotropic pyrimidine com-
pound, MS-818, may activate migratory Schwann cells in peripheral 
nerve regeneration" Brain Research 787(1998) 337-340. 
Watanabe et al., "A Neurotrophic Pyrimidine Compound, MS-818, 
Enhances EGF-Induced Restoration of Gastric Epithelial Wounds in 
Vitro" J Clin. Gastroenterol 1988:27(Suppl. l)S105-Sl09. 
Sugiyama et al., "Acceleration by MS-818 of Early Muscle Regen-
eration and Enhanced Muscle Recovery after Surgical Transection" 
Muscle & Nerve Feb. 2002 218-229. 
Alvarez-Buylia et al., 1997, J Neurobiology 33: 585-601. 
Benninger et al., 2000, Brain Pathol. 10: 330-341. 
Blakemore et al., 1991, TrendsNeurosci.14: 323-327. 
Blakemore et al., 2000, Cell Transplant. 9: 289-294. 
Brannen et al., 2000, Neuroreport 11: 1123-8. 
Carpenter et al., 1999, Experimental Neurology 158: 265-278. 
Cattaneo et al., 1996, Mo!. Brain Res. 42: 161-66. 
Doetsch et al., 1999, Cell 97: 703-16. 
Eckenstein et al., 1994, Biochem. Pharmacol. 47: 103-110. 
Fricker et al., 1999, J Neurosci. 19: 5990-6005. 
Frolichsthal-Schoeller et al., 1999, NeuroReport 10: 345-351. 
Gonzalez et al., 1995, Brain Res. 701: 201-226. 
Gould et al., 1999, Science 286: 548-552. 
Hatton et al., 1992, Glia 5: 251-258. 
Johansson et al., 1999, Cell 96: 25-34. 
Kurimoto et al., 2001, Neurosci Let. 306: 57-60. 
Lundberg et al., 1996, Exp. Neural. 139: 39-53. 
Nishida et al., 2000, Invest Ophthalmol Vis Sci 41: 4268-74. 
Pundt et al., 1995, Brain Res. 695: 25-36. 
Qu et al., 2001, Neuroreport 12: 1127-32. 
Rosser et al., 2000, Eur. J Neurosci. 12: 2405-2413. 
Rubio et al., 2000, Mo!. Cell. Neurosci. 16: 1-13. 
Svendsen et al., 1998, J Neurosci. Methods 85: 141-152. 
Svendsen et al., 1999, Brain Pathol. 9: 499-51. 
Warfvinge et al., 2001, Exp. Neurol. 169: p. 1-12. 
Williams et al., 1996, J Comp. Neural. 370: 147-158. 
Daadi et al Generation of tyrosine hydroxylase-producing neurons 
from precursors of the embryonic and adult forebrain. The Journal of 
Neuroscience. Jun. 1, 1999, vol. 19, No. 11, pp. 4484-4497. 
Murphy et al. Neural Stem Cells. Journal oflnvestigative Dermatol-
ogy Symposium Proceedings. Aug. 1997, vol. 2, No. 1, pp. 8-13. 
Mazurova et al. New therapeutic approaches for the treatment of 
Huntington'sdisease.ActaMedica2001, vol. 44, No. 4, pp. 119-123. 
Memberg et al. Proliferation, differentiation and survival of rat sen-
sory neuron precursors in vitro require specific trophic factors. 
Molecular and Cellular Neuroscience. Aug. 1995, vol. 6, No. 4, pp. 
323-335. 
Andrews et al. TNFa potentiates IFN g-induced cell death in 
oligodendrocyte progenitors. Journal of Neuroscience Research. 
Dec. 1998, vol. 54, No. 5, pp. 574-583. 
Brewer. Regeneration and proliferation of embryonic and adult rat 
hippocampal neurons in culture. Experimental Neurology. Sep. 
1999, vol. 159, No. 1, pp. 237-247. 
International Preliminary Examination Report of Nov. 5, 2003 for 
PCT/US03/01254. 
International Preliminary Examination Report of Dec. 23, 2003 for 
PCT/US03/01014. 
International Preliminary Examination Report of Dec. 31, 2003 for 
PCT/US03/01258. 
Pagan, R. et al. Epithelial-mesenchymal transition of cultured rat 
neonatal hepatocytes is differentially regulated in response to epider-
mal growth factor and dimethyl sulfoxide. 1997, Hepatology, vol. 25, 
No. 3, pp. 598-606. 
US 7,635,467 B2 
Page 3 
Cheng, C. et al. In vivo proliferation, migration and phenotypic 
changes of Schwann cells in the presence of myelinated fibers. 
Neuroscience. Nov. 2002, vol. ll5, No. 1, pp. 321-329. 
Bayarshaihan, D. et al. Rapid identification of novel chondrocyte-
specific gene by RNA differential display. Biochem. And Biophys. 
Res. Comm. 1995, vol. 220, pp. 449-452. 
Sanjo et al. A novel neutrophic pyrimidine compound MS-818 
enhances neurotrophic effects of basic fibriblast growth factor. Jour-
nal of Neuroscience Research, 1998, vol. 54, pp. 604-612. 
Qu et al., (2001), Society for Neuroscience Abstracts, "In vivo dif-
ferentiation and migration properties of mesenchymal stem cells", 
vol. 27(1), p. 969; 3151 Annual Meeting of the Society for 
Neuroscience; San Diego, California, USA; Nov. 10-15, 2001. 
Qu et al., (2002), Society for Neuroscience Abstracts Viewer and 
Itinerary Planner, "A seven fold increase in neural stem cell popula-
tion is induced by pyrimidine derivative MS-818", Abstract No. 
825.8, 32"d Annual Meeting of the Society for Neuroscience; 
Orlando, Florida, USA; Nov. 2-7, 2002. 
Ferrari et al., (1998), Muscle regeneration by bone marrow-derived 
myogenic progenitors, Science 279: 1528. 
Gussoni et al., (1999), Dystrophin expression in the mdx mouse 
restored by stem cell transplantation, Nature 401: 390. 
Petersen et al., (1999), Bone marrow as a potential source of hepatic 
oval cells, Science 284: 1168. 
Pereira et al., (1995), Cultured adherent cells from marrow can serve 
as long-lasting precursor cells for bone, cartilage, and lung in irradi-
ated mice, PNAS 92: 4857. 
Prockop et al., (1997), Marrow stromal cells as stem cells for 
nonhematopoietic tissues, Science 276: 71. 
Pittenger et al., (1999), Multilineage potential of adult human 
mesenchymal stem cells, Science 284: 143. 
Kessler PD, ( 1999), Myoblast cell grafting into heart muscle: cellular 
biology and potential applications, Annu. Rev. Physiol. 61: 219. 
Kohyarna, Jun, et al., "Brain From Bone: Efficient 'Meta-Differen-
tiation' of Marrow Stroma-Derived Mature Osteoblasts to Neurons 
with Noggin or A Demethylating Agent," Differentiation, 2001, vol. 
68, pp. 235-244. 
Burt et al. Treatment of autoimmune disease by intense immunosup-
pressive conditioning and autologous hernatopoietic stem cell trans-
plantation. Blood, 1998, vol. 92, No. 10, pp. 3505-3514. 
Awaya, Akira, et al., "Neurotropic Pyrimidine Heterocyclic Com-
pounds. I. The Newly Synthesized Pyrimidine Compounds Promote 
Neurite Outgrowth of GOTO and Neuro 2a Neuroblastorna Cell 
Lines, and Potentiate Nerve Growth Factro (NGF)-Induced Neurite 
Sprouting of PC 12 Cells," Bio. Pharm. Bull., 1993, 16(3), pp. 248-
253. 
Noda, Masayuki, et al., "Increase of Nerve Regeneration Capacity by 
New Neurotrophic Pyrimidine Derivative MS-430," Gen. Pharmac., 
1998, vol. 31, No. 5, pp. 821-824. 
Ohnishi, Akio, et al., "The Effect of MS-430, a Synthetized 
Pyrimidine Compound, on regeneration of Nerve Fibers of Rats after 
Crush Injury," JUoeh, 1995, 17(2), pp. 131-139. 
Sager, Ruth, et al., "Pre-Adipocyte Determination either by Insulin or 
by 5-Azacytidine," Proc. Natl. Acad. Sci., Cell Biology, 1982, vol. 79, 
pp. 480-484. 
Brickman et al. The Journal of Biological Chemistry, 1995, 
270:24941-24948. 
* cited by examiner 
U.S. Patent Dec. 22, 2009 Sheet 1of35 US 7,635,467 B2 
'1 
[-~------
U.S. Patent 
0 
Lil 
M 
Dec. 22, 2009 
0 
0 
M 
0 
LI') 
N 
0 
0 
N 
Sheet 2 of 35 
0 
Ln 
0 
0 
0 
Ln 
US 7,635,467 B2 
0 
U.S. Patent Dec. 22, 2009 Sheet 3 of 35 US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 4 of 35 US 7 ,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 5 of 35 US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 6 of 35 US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 7 of 35 
<l) 
> 
....... 
....... 
50 
'Cii 40 0 <l) 
0.... H 
I ::s 
i::::: ~ 30 
....... ::s 
"3 0 
,.!::J ~ 
::s ....... 20 ~ c:IJ 
..n = <l) ~ 0 10 
bl) 
> 
-ct: 0 
<l) 
> 
....... 
50 
• -;:: <l) 40 
rf:J H 
&a 
~ "5 30 
-ct: 0 
~ .s 
c:J c:IJ 20 
-~ Q) 
00 ° 10 
> 
<r: 
0 
50 
<l) 
> 
·.;: <l) 40 
. ..,... H 
r/:J ::s 0 ....... 
o....-
1 ::s 30 
"tj'" 0 
0 .s 
~ ~ 20 
-on 8 
..< 10 
0 
** ** 
5 day 7 day 
Number of Days in vitro 
tt 
** 
** 
5 day 7 day 
Number of Days in vitro 
** 
t 
** ** 
5 day 7 day 
Number of Days in vitro 
Figure 6 (II) 
US 7,635,467 B2 
U.S. Patent 
Lr 
Dec. 22, 2009 
. ;'1J¥c 
'>;;:·~-
, .. 
:/:~):?~ 
'{~{~' 
,-;--""' 
"· . \ ~ 
Sheet 8 of 35 US 7 ,635,467 B2 
"-~~~~~~~~ 
. '(_/( ) . 
./{ 
:f i'" 
,;·q,. 
u; 
1: 
'-"'>.{ 
1}1._ . 
~<-< 
.. . ,r~::..· - J.~-.'j: -
. . . 
;~\J,<~y.\f d<i 
t ~~~·-~~?c~~:~.:1:. = --
• •• <J 
··~_l;. 
'!;!',( 
-~- .,_ 
; 'I 
-~ 
I 
' 
·- j 
U.S. Patent Dec. 22, 2009 Sheet 9 of 35 US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 10 of 35 US 7 ,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 11 of 35 US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 12 of 35 US 7,635,467 B2 
U.S. Patent 
.... 
. -~. 
- .. 
: ..... -' ... ..I • 
.. 
., 
~·· 
-: ,f 
" 
•·· 
1. 
r 
Dec. 22, 2009 
-i.'' 
. ' ' 
•· 
,, 
.. 
.: .. .:-4-
' .. .1-:-:: .. ; 
. ' 
' ., 
...... 
., 
.... i 
·-· -
' j 
.. 
,. 
·. 
• > 
• i ·,; .. 
-. , ~ ,- .. ~' 
.. •·.:., I . ~~~ .. 
. (1 
• ,, ,,: ·1 ... 
..,_ .. · 
_ . .. , 
.... . 
.-
.. 
,• 
.. 
,•,-
\ 
... 
.. -., 
~' 
. 
Sheet 13 of 35 
• 
. .
• 
.. _ 
.. 
. •' 
•. 
,. 
... 
. - . 
• > 
' ... ~ 
!-·.;l., 
-: ~; 
' . ,. 
.. \ 
, I 
. 
. ' 
f 
. : -. 
.  
US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 14 of 35 US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 15 of 35 US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 16 of 35 US 7 ,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 17 of 35 US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 18 of 35 US 7 ,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 19 of 35 US 7,635,467 B2 
... 
"I 
U.S. Patent Dec. 22, 2009 
;--:~ ·-,-,,-1! c· -.,- ~~-~?009·-----. -_ - ·o---. 
I 
i 
( 
L 
I 
'. 
' 
I. 
e t 
,! 
Sheet 20 of 35 US 7 ,635,467 B2 
~----~~=---=-==-=-==-=·-:---==-c---=--=-·C'.::l 
-m 
f/J 
ro 
..a 
E 
:::r 
Ii-· 
Q) 
u-, 
·-
t 
c:1 
...... i 
_....,, 
Q), 
•Q)' 
ct: 
'. 
,.. 
.c '. 
RS 
c 
·1 
_j 
U.S. Patent Dec. 22, 2009 Sheet 21 of 35 US 7 ,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 22 of 35 
.. ~0 
•ec 'Ll , I 
US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 23 of 35 US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 24 of 35 US 7,635,467 B2 
en 
m100--~~~~~~~~~~~~~~ ....... 
u 
~600 
·-+-' 
~500 
0.. 
:::J 400 
"E 
co 300 
'+-
0 
0;200 
.0 
E 100 
::l 
D Wild type 
~ Reeler ( +/-) 
II Reeler (-/-) 
z 0--................. 
hippocampus olfactory svz 
Figure 22 
U.S. Patent Dec. 22, 2009 Sheet 25 of 35 US 7 ,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 26 of 35 US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 27 of 35 US 7,635,467 B2 
• 
\ ... 
/...,-. 
·-cc 
· .. 
'\. 
,. 
U.S. Patent Dec. 22, 2009 Sheet 28 of 35 US 7,635,467 B2 
U.S. Patent 
' (._~ 
•J !· 
Ji' \; \ "' \J 
' tJ ~ {J 
'. 
' ~· 
~ 
•, 
Dec. 22, 2009 
.-~ 
• 3 
..,.. 
'r~ 
,, 
.,_ 
q• 
· .. y 
- .. 
'/ 
r 
·' •·, 
Sheet 29 of 35 US 7 ,635,467 B2 
·, 
"' 
. . 
\ 
.\, {' 
.~ 
.- . .. . ~. 
~·· . 
.. 
•. 
.. \~. . . .. '· ~ 
. 
' 
~t. ~ 't.~ 
U.S. Patent 
,. 
l. 
Dec. 22, 2009 
' '~:i;~:~~_:, 
\.~-··~' . 
... •· .. '-!!" 
'"\.-' \," 
\·.· 
Sheet 30 of 35 US 7,635,467 B2 
~- ·~ 
',:7 
"-! 
j."·. 
\ - '-':'• - ~ .. 
- ....... ·\.1.::"" 
'-. -.~'.~ '1~-,!j ·i~ 
U.S. Patent Dec. 22, 2009 Sheet 31of35 US 7 ,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 32 of 35 US 7,635,467 B2 
90 
* 
U) 
- 80 -Q) 
* 
0 70 
-c Q) 60 c .... 
·-cu :J c 
·- 50 .... .c c.. ·-c: Cl. -:J <( :J Q) 40 <( ... .c I.. I LL ~ LL -i :::I 30 C> -i C> "4i' -i 
·- co. -i 
"'C -i 20 * 
-i 
'+- Q1 0 
* ~ 10 c 
0 
0 25 50 100 
sAPP concentration (ng/ml) 
Figure 30 
U.S. Patent Dec. 22, 2009 Sheet 33 of 35 US 7,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 34 of 35 US 7 ,635,467 B2 
U.S. Patent Dec. 22, 2009 Sheet 35 of 35 US 7,635,467 B2 
US 7,635,467 B2 
1 
MAMMALIAN MULTIPOTENT STEM CELLS 
AND COMPOSITIONS, METHODS OF 
PREPARATION AND METHODS OF 
ADMINISTRATION THEREOF 
This application is related to U.S. Provisional Patent Appli-
cations Ser. No. 60/348,473, filed Jan. 14, 2002, and Ser. No. 
60/357,783, filed Feb. 19, 2002, and Ser. No. 60/376,257, 
filed Apr. 29, 2002, and Ser. No. 60/381,138, filed May 8, 
2002, and Ser. No. 60/404,361, filed Aug. 19, 2002, and Ser. 
No. 60/430,381, filed Dec. 2, 2002, the disclosures of each of 
which are expressly incorporated by reference herein. 
This invention was made with support from the U.S. Gov-
ermnent through the National Institutes of Health, grant no. 
R03-AG19874. The govermnent has certain rights in this 
invention. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to novel mammalian multipotent 
stem cells (MSCs), compositions thereof, and methods of 
preparing and administering these cells. In one aspect, the 
invention relates to methods of making more developmen-
tally potent cells from less developmentally potent cells. In 
another aspect, the invention relates to cells prepared accord-
ing to the methods of the invention. In another aspect, the 
invention relates to pharmaceutical compositions comprising 
the more developmentally potent cells of the invention. In 
another aspect, the invention relates to cellular preparations 
for cell or tissue regeneration comprising said more develop-
mentally potent cells of the invention. In another aspect, the 
invention relates to methods for regenerating cells or tissue 
comprising the step of administering the more developmen-
tally potent cells of the invention to a tissue in an animal in 
need thereof. In another aspect, the invention relates to a 
method for treating a human or animal having a neurological 
or corporal deficit comprising the step of administering the 
more developmentally potent cells of the invention or termi-
nally differentiated cells produced according to the invention 
to an animal, including human, in need thereof. In another 
aspect, the invention relates to a method of making and using 
2 
Publication Nos. WO 93/01275, WO 94/09119, WO 
94/10292, WO 94/16718 and Cattaneo et al., 1996, Mal. 
Brain Res. 42: 161-66. NSCs from the embryonic and adult 
rodent central nervous system (CNS) have been isolated and 
further propagated in vitro in a variety of culture systems. 
See, e.g., Frolichsthal-Schoeller et al., 1999, NeuroReport 10: 
345-351; Doetsch et al., 1999, Cell 97: 703-716. NSCs from 
the human fetal brain have been cultured using serum-free 
medium supplemented with epidermal growth factor (EGF) 
10 and/or basic fibroblast growth factor (bFGF). See, e.g., 
Svendsen et al., 1998, J. Neuroscience Methods 85: 141-152; 
Carpenter et al., 1999, Experimental Neurology 158: 265-
278. NSCs cultured utilizing these serum-free, mitogen-
supplemented methods generally form substantially undiffer-
15 entiated, clustered aggregates. Upon removal of the 
mitogen(s) and provision of a substrate, the stem cells differ-
entiate into neurons, astrocytes and oligodendrocytes. 
While the synaptic connections involved in neural circuits 
are continuously altered throughout the life of the individual, 
20 due to synaptic plasticity and cell death, neurogenesis, the 
generation of new neurons, was thought to be complete early 
in the postnatal period. The discovery ofMNSCs in the adult 
brain (see, e.g., Alvarez-Buylla et al., 1997, J. Neurobiology 
33: 585-601; Gould et al., 1999, Science 286: 548-552) has 
25 brought significant changes in the theory on neurogenesis as 
the presence ofMNSCs in the adult brain suggests that regen-
eration of neurons can occur throughout life. Nevertheless, 
age, physical and biological trauma or neurodegenerative 
disease-associated loss of brain function, herein referred to as 
30 a "neurological deficit," can far outweigh any potential restor-
ative effects due to endogenous neurogenesis. As a result, 
transplantation ofNSCs is a potentially valuable treatment for 
those suffering from the loss of, or loss of appropriate, brain 
function due to age, physical and biological trauma or neu-
35 rodegenerative disease (i.e., a neurological deficit). 
Due to the advancing average age of the population, and 
concomitantly increased incidence of neurological deficit 
that accompanies advancing age, treatment of neurodegen-
erative diseases has become a major concern. Such diseases, 
40 including Alzheimer's disease, Huntington's chorea and Par-
kinson's disease, have been linked to neuronal degeneration 
at specific locations in the brain, leading to the inability of the 
brain region to synthesize and release neurotransmitters that a terminally differentiated cell utilizing the more develop-
mentally potent cells of the invention. In another aspect, the 
invention relates to a method of changing the phenotype of a 45 
cell. 
are vital to neuronal signaling. 
Neurodegeneration also encompasses many conditions 
and diseases, age-related or not, that result in neuronal loss. 
2. Background of the Related Art 
Stem cells are often defined as self-renewing and multipo-
tent, with the ability to generate diverse types of differentiated 
cells. As such, they show promise in the treatment ofneuro- 50 
logical and corporal deficits, or any loss or diminishment of 
tissue function due to age, disease, trauma or other factor. 
However, such treatments have faced significant hurdles that 
These conditions include CNS trauma, such as stroke and 
epilepsy, as well as diseases that result in neuronal loss, 
including amyotrophic lateral sclerosis and cerebral palsy. 
Degeneration in a brain region known as the basal ganglia 
can lead to diseases with varied and different cognitive and 
motor symptoms, depending on the exact location of the 
lesion. The basal ganglia consists of many separate regions, 
including the striatum (which consists of the caudate and have yet to be substantially overcome. 
NSCs and Neurological Deficits 
Because one important focus of stem cell replacement 
therapies has been neurological disorders, neural stem cells, 
and particularly fetal neural stem cells, have been a major 
research target. During development of the central nervous 
system (CNS), multipotent neural stem cells (MNSCs), also 
known as neural stem cells (NSCs ), proliferate, giving rise to 
transiently dividing progenitor cells that eventually differen-
tiate into the cell types that compose the adult brain, including 
neurons, astrocytes and oligodendrocytes. NSCs have been 
isolated from several mammalian species, including mice, 
rats, pigs and humans. See, e.g., International Application, 
55 putamen), the globus pallidus, the substantia nigra, substantia 
innominata, ventral pallidum, nucleus basalis of Meynert, 
ventral tegmental area and the subthalamic nucleus. 
Degeneration in the basal ganglia can lead to motor defi-
cits. For example, Huntington's chorea is associated with 
60 degeneration of neurons in the striatum, which leads to invol-
untary jerking movements. Degeneration of a small region 
called the subthalamic nucleus is associated with violent 
flinging movements of the extremities in a condition called 
ballismus, while degeneration in the putamen and globus 
65 pallidus are associated with a condition of slow writhing 
movements or athetosis. In Parkinson's disease, degeneration 
is seen in another area of the basal ganglia, the substantia 
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nigra par compacta. This area normally sends dopaminergic 
connections to the dorsal striatum, which is important in 
regulating movement. Therapy for Parkinson's disease has 
centered upon restoring dopaminergic activity to this circuit. 
4 
Alzheimer's disease patients exhibit a profound cellular 
degeneration of the forebrain and cerebral cortex. Further, a 
localized area of the basal ganglia, the nucleus basalis of 
Meynert, appears to be selectively degenerated. This nucleus 
normally sends cholinergic projections to the cerebral cortex 
that are thought to participate in cognitive functions including 10 
or by the culturing of cells in vitro with altered growth char-
acteristics. Moreover, adverse immune response potential, 
the use of retroviruses to immortalize cells, the potential for 
the reversion of these cells to an amitotic state, and the lack of 
response by these cells to normal growth-inhibiting signals 
make such cell lines sub-optimal for widespread use. Like-
wise, xenobiotic transplantation has lacked significant suc-
cess. 
Another approach to neurotransplantation involves the use 
of genetically engineered cell types or gene therapy. How-
ever, there still exists a risk of inducing an immune reaction 
with these cells. In addition, retrovirus mediated transfer may 
result in other cellular abnormalities. Also, cell lines pro-
duced by retrovirus-mediated gene transfer have been shown 
memory. 
The objective of most CNS therapies is to regain the par-
ticular chemical function or enzymatic activity lost due to 
cellular degeneration. Administration of pharmaceutical 
compositions has been the main treatment for CNS dysfunc-
tion. Unfortunately, this type of treatment has many compli-
cations, including the limited ability to transport drugs across 
the blood-brain barrier, and drug-tolerance acquired by 
patients to whom these drugs are administered for long peri-
ods. 
15 to gradually inactivate their transferred genes following 
transplantation and further may also not achieve normal neu-
ronal connections with the host tissue. 
While currently available transplantation approaches rep-
resent an improvement over other available treatments for 
20 neurological disorders, they suffer from significant draw-
backs. The inability in the prior art of the transplant to fully 
integrate into the host tissue, and the lack of availability of 
suitable cells in unlimited amounts from a reliable source for 
Transplantation of multipotent stem cells may avert the 
need not only for constant drug administration, but also for 
complicated drug delivery systems necessitated by the blood-
brain barrier. In practice, however, significant limitations 
have been found in this technique as well. First, cells used for 25 
transplantation that carry cell surface molecules of a differ-
entiated cell from a donor can induce an immune reaction in 
the recipient, a problem that is exacerbated by the physical 
damage caused by injection of cells directly into the affected 
area of the brain. In addition, the neural stem cells must be at 30 
a developmental stage where they are able to form normal 
neural connections with neighboring cells. For these reasons, 
initial studies on neurotransplantation centered on the use of 
fetal cells. 
grafting are significant limitations of neurotransplantation. 
Studies utilizing intra-tissue injection of dissociated and par-
tially differentiated NS Cs have shown little promise (see, e.g., 
Benninger et al., 2000, Brain Pathol. 10: 330-341; Blakemore 
et al.. 2000, Cell Transplant 9: 289-294; Rosser et al., 2000, 
Eur. J. Neurosci. 12: 2405-2413; Rubio et al., 2000, Mal. Cell 
Neurosci. 16: 1-13). The results have generally been poor 
because, among many considerations, the dissociation of 
clusters ofNSCs is known to cause immediate senescence of 
the NSCs and increase the vulnerability ofNSCs in culture. 
See, e.g., Svendsen et al., 1998, J. Neurosci. Methods 85: 
Manimalian fetal brain tissue has proven to have reason-
able survival characteristics upon immediate transplantation. 
Increased survival capability of fetal neurons is thought to be 
due to the reduced susceptibility of fetal neurons to anoxia 
compared to adult neurons. An additional factor favoring 
survival of fetal cells is the lack of cell surface markers on 
fetal cells, whose presence may lead to rejection of grafted 
tissue from adults. However, although the brain is considered 
an immunologically privileged site, some rejection of even 
fetal tissue can occur. Therefore, the ability to use heterolo-
gous fetal tissue is limited by tissue rejection and the need for 
immunosuppressant drugs. 
The use of large quantities of aborted fetal tissue presents 
other difficulties as well. Fetal CNS tissue is composed of 
more than one cell type, and thus is not a well-defined tissue 
source. In addition, there are doubts as to whether an adequate 
and constant supply of fetal tissue would be available for 
transplantation. For example, in the treatment of MPTP-in-
duced Parkinsonism, tissue from as many as 6 to 8 fetuses can 
be required for successful implantation into the brain of a 
single patient. There is also the added problem of the potential 
for contamination during fetal tissue preparation. Since these 
tissue may already be infected with a bacteria or virus, expen-
sive diagnostic testing is required for each fetus used. Even 
comprehensive diagnostic testing might not uncover all 
infected tissue. For example, there can be no guarantee that a 
sample is HIV-free, because antibodies to the virus are gen-
erally not present until several weeks after infection. 
In addition to fetal tissue, there are other potential sources 
of tissue for neurotransplantation, including cell lines and 
genetically engineered cell types, but both sources present 
problems. Cell lines are immortalized cells that are derived, 
inter alia, by transformation of normal cells with an oncogene 
35 141-152. Further, regardless of adverse immune responses 
due to foreign tissue being introduced into the brain, the 
trauma caused by the physical introduction of cells directly 
into the damaged area can induce the recruitment of immune 
cells by the host that can eliminate the transplanted cells. 
40 Thus, significant problems with the use ofNSCs to ameliorate 
neurological deficits remain. 
As described herein, neurological deficits also include 
non-brain tissues such as, for example, the eye and spinal 
cord. In addition, corporal deficits are a target for ameliora-
45 tion utilizing multipotent stem cells. A "corporal deficit" is a 
disorder caused by a wide variety of diseases and injuries, 
resulting in trauma, malfunction, degeneration or loss of 
muscle such as, for example, cardiac muscle due to myocar-
dial infarction. Other examples include malfunction, degen-
50 eration or loss of other cells and tissues apart from those 
discussed in the neurological deficit section above such as, for 
example, internal organs. For example, liver function can be 
adversely affected by, among other things, disease (e.g., cir-
rhosis or hepatitis), trauma or age. The problems described 
55 above in using NSCs to remedy neurological deficits of the 
brain also apply to neurological deficits in other tissues, such 
as the eye, and corporal deficits. 
There exists a need in the art for improved methods for 
introducing multipotent stem cells to diseased, aged or dam-
60 aged mammalian brain. In addition, there remains a need for 
methods of using or administering the multipotent stem cells 
of the invention, or pharmaceutical preparations thereof, to 
the affected, damaged or degenerated tissue, wherein the stem 
cells can differentiate in a manner appropriate for the host 
65 tissue and enable the replacement of damaged cells, repair of 
damages tissue and, optionally, amelioration of functional 
loss. There also remains a need in the art for a reliable source 
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of unlimited numbers of cells for transplantation, particularly 
cells that are specifically adapted for and capable of prolif-
eration, migration, and differentiation in marmnalian brain or 
other tissues when introduced thereto. Furthermore, there 
exists a need in the art for methods for repairing damaged 
neural and other tissues in as non-invasive a fashion as pos-
sible, especially by inducing multipotent stem cells to prolif-
erate and differentiate in vivo into, for example, neurons, 
astrocytes, and oligodendrocytes in the brain or, for example, 
rod or cone photoreceptor cells, horizontal cells, bipolar cells, 10 
amacrine cells, ganglion cells, Muller cells, and nerve cells, 
Buchs, chorid and retinal pigment epithelium (RPE) cells in 
eye tissue. 
6 
developmentally potent cell is obtained from any tissue con-
taining stem cells including but not limited to zygote, blasto-
cyst, embryo, fetus, infant juvenile or adult, and optionally, a 
human species ofany of the preceding embodiments, whether 
naturally occurring or engineered. As provided herein, the 
methods of the invention provide one or a plurality of more 
developmentally potent cells that exist singly or form clusters 
of two or more cells. 
In the practice of this aspect of the invention, the phenotype 
of the less developmentally potent cell is changed when it 
becomes a more developmentally potent cell. Thus, the inven-
tion provides methods for changing a first phenotype of a less 
developmentally potent cell into a second phenotype of more 
developmentally potent cell, wherein said second phenotype 
SUMMARY OF THE INVENTION 
This invention provides methods for producing multipo-
tent stem cells, and cells produced by those methods. In 
particular, the invention provides reagents and methods for 
efficiently producing stem cells that can be re-introduced into 
an animal in need thereof to alleviate neurological or corporal 
disorders. 
15 is determined by the environment surrounding the substituted 
deoxynucleotide or deoxynucleoside-contacted cell. In pre-
ferred embodiments, the less developmentally potent cell is a 
stem cell, more preferably a hematopoietic stem cell, a neural 
stem cell, an epithelial stem cell, an epidermal stem cell, a 
20 retinal stem cell, an adipose stem cell and a mesenchymal 
stem cell. 
In a first aspect, the invention provides methods for making 
In a second aspect, the invention provides one or a plurality 
of more developmentally potent cells using the methods of 
the invention. In certain embodiments, the cells form a cluster a more developmentally potent cell from a less developmen-
tally potent cell. In one embodiment, the method comprises 
the step of contacting a less developmentally potent cell with 
an effective amount of a substituted deoxynucleotide or 
deoxynucleoside compound for an effective period, wherein 
the substituted deoxynucleotide or deoxynucleoside com-
pound-contacted, less developmentally potent cell becomes a 
more developmentally potent cell capable of differentiating 
to a less developmentally potent cell of its lineage of origin or 
25 of two or more cells. As provided herein, said more develop-
mentally potent cells preferably comprise less than about 50 
percent, more preferably less than about 25 percent, even 
more preferably less than about 10 percent, even more pref-
erably less than about 5 percent, and even more preferably 
30 less than about 1 percent redifferentiated cells. "Redifferen-
tiated cells" as used herein, refers to cells that have terminally 
differentiated during the performance of the methods herein 
prior to migration, differentiation and incorporation into host a different lineage. In certain embodiments, the inventive 
methods further comprise the step of co-culturing the less 
developmentally potent cell contacted with substituted 35 
deoxynucleotide or deoxynucleoside compounds with neu-
ral-lineage cells or media conditioned with neural-lineage 
cells, wherein the substituted deoxynucleotide or deoxy-
nucleoside compound-contacted, less developmentally 
potent cell becomes a more developmentally potent cell 40 
capable of differentiating to a less developmentally potent 
cell of its lineage of origin or a different lineage. In additional 
embodiments, the method comprises the step of contacting 
the less developmentally potent cell with a substituted deoxy-
nucleotide or deoxynucleoside compound in an uncoated 45 
flask or a flask that has been treated to repel the cells. In yet 
further embodiments, the less developmentally potent cell is 
further contacted with a growth factor such as fibroblast 
growth factor, epidermal growth factor or a combination 
thereof. Alternatively, the less developmentally potent cells 50 
are contacted additionally with heparin. 
Exemplary substituted deoxynucleotide or deoxynucleo-
side compounds as provided by the invention include but are 
not limited to halogen-substituted (halo-substituted) deoxy-
nucleotides or deoxynucleosides, such as, for example, bro- 55 
modeoxyuridine, iododeoxyuridine, bromodeoxyguanosine, 
iododeoxycytosine as well as alkyl-substituted species such 
as, for example, methyldeoxythymidine. A most preferred 
species is bromodeoxyuridine (BrdU). In certain embodi-
ments, the less developmentally potent cell is contacted with 60 
an effective amount of substituted deoxynucleotide or deoxy-
nucleoside compounds for an effective period. In some 
embodiments, the less developmentally potent cell is a tissue 
(or tissue-specific) stem cell, such as a hematopoietic stem 
cell, a neural stem cell, an epithelial stem cell, an epidermal 65 
stem cell, a retinal stem cell, an adipose stem cell and a 
mesenchymal stem cell. In certain embodiments, the less 
tissue. 
In yet further aspects of the invention are provided phar-
maceutical compositions comprising said more developmen-
tally potent cells prepared according to the methods of the 
invention and a pharmaceutically-acceptable carrier or 
excipient. The invention provides such pharmaceutical com-
positions comprising said more developmentally potent cells 
that are tissue stem cells for use in cell or tissue regeneration 
or for correcting a disease or disorder in a tissue or animal in 
need thereof. 
Thus, the invention also provides methods for using the 
pharmaceutical compositions provided herein to treat an ani-
mal in need thereof by administering the more developmen-
tally potent cells thereto. In certain preferred embodiments, 
the more developmentally potent cells comprise a cluster of 
two or more of the more developmentally potent cells. Pref-
erably, the animal has a corporal or neurological deficit that 
can be treated or ameliorated by administration of said more 
developmentally potent cells, such as a deficit caused by a 
neurodegenerative disease, a traumatic injury, a neurotoxic 
injury, ischemia, a developmental disorder, a disorder affect-
ing vision, an injury or disease of the spinal cord, a demyeli-
nating disease, an autoimmune disease, an infection, an 
inflammatory disease, or corporal disease, disorder, injury, 
trauma, malfunction, degeneration or loss. In preferred 
embodiments, the one or plurality of more developmentally 
potent cells are capable of migrating to an area of tissue 
damage, differentiating in a tissue-specific manner and func-
tioning in a manner that reduces the neurological or corporal 
deficit. As provided by the methods of the invention herein, 
the cells are administered by injecting one or a plurality of 
more developmentally potent cells with a syringe, inserting 
the more developmentally potent cells with a catheter or 
surgically implanting the more developmentally potent cells. 
US 7,635,467 B2 
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In certain embodiments, the more developmentally potent 
cells are injected with a syringe into a body cavity that is 
fluidly-connected to the area of neurological or corporal defi-
cit. In certain preferred embodiments, the body cavity is a 
brain ventricle. In other embodiments, the more developmen-
tally potent cells are inserted with a catheter into a body cavity 
that is fluidly-connected to the area of neurological or corpo-
ral deficit. In certain preferred embodiments, the body cavity 
8 
stem cell, an adipose stem cell and a mesenchymal stem cell, 
in preferred embodiments a mesenchymal cell. 
Alternatively, the invention provides a method of treating a 
patient having a neurological deficit or corporal deficit with 
terminally differentiated cells, that is, with cells that are ter-
minally differentiated prior to administration. Such termi-
nally differentiated cells can be administered at the site of 
neurological or corporal deficit or systemically, for example, 
intravenously. 
In yet another embodiment, the invention relates to treating 
a stem cell, excluding those of neural origin, such that it is 
converted into a more developmentally potent cell, which 
enables it to differentiate into the various cell types found in 
eye tissue, inter alia, chorid, Buchs and retinal pigment epi-
is a brain ventricle. In still further additional embodiments, 
the more developmentally potent cells are surgically 10 
implanted into a body cavity that is fluidly-connected to the 
area of neurological or corporal deficit. In certain preferred 
embodiments, the body cavity is a brain ventricle. The more 
developmentally potent cells can also alternatively be 
inserted using a syringe or catheter or surgically implanted 
directly at the site of the neurological or corporal deficit or 
systemically (e.g., intravenously). 
15 thelium cells, rod and cone photoreceptor cells, horizontal 
cells, bipolar neurons, amacrine, ganglion and optic nerve 
cells. These non-limiting, exemplary cell types found in eye 
tissue are collectively referred to as retinal cells. The methods 
comprising the step of contacting more developmentally Administration of the one or a plurality of more develop-
mentally potent cells into an animal results in said cells dif-
ferentiating into a terminally-differentiated cell. Thus, the 
invention provides methods for making a terminally-differ-
entiated cell, comprising the step of administering the more 
developmentally potent cells of the invention into an animal 
20 potent cells of the invention with an effective amount of one 
or a combination of growth factor selected from the group 
consisting of TGF-b3, IGF-1 and CNTF for an effective 
period such that the growth factor-contacted cells can differ-
in need thereof. As provided by the methods of the invention 25 
herein, the cells are administered by injecting the more devel-
opmentally potent cells with a syringe, inserting the more 
developmentally potent cells with a catheter or surgically 
implanting the more developmentally potent cells. In certain 
embodiments, the more developmentally potent cells are 30 
injected with a syringe into a body cavity that is fluidly-
connected to the area of neurological or corporal deficit. In 
certain preferred embodiments, the body cavity is a brain 
ventricle. In other embodiments, the more developmentally 
potent cells are inserted with a catheter into a body cavity that 35 
is fluidly-connected to the area of neurological or corporal 
deficit. In certain preferred embodiments, the body cavity is a 
brain ventricle. In still further additional embodiments, the 
more developmentally potent cells are surgically implanted 
into a body cavity that is fluidly-connected to the area of 40 
neurological or corporal deficit. In certain preferred embodi-
ments, the body cavity is a brain ventricle. The more devel-
opmentally potent cells can also alternatively be inserted 
using a syringe or catheter or surgically implanted directly at 
the site of the neurological or corporal deficit or systemically 45 
(e.g., intravenously). 
entiate into retinal cells. 
In another aspect, the invention provides a method of alter-
ing the migration and/or differentiation of endogenous or 
exogenous multipotent stem cells in a mammal by modulat-
ing the levels of APP and/or reelin in the mammal. In certain 
embodiments, the exogenous multipotent stem cells can be 
the more developmentally potent cells produced according to 
the methods of the invention. In certain other embodiments, 
the more developmentally potent cells are administered as 
part of the pharmaceutical compositions or the cellular prepa-
rations of the invention. In other embodiments, the amount of 
reelin in a manimal is altered by administration of reelin 
protein, a drug that alters reelin levels, or a vector that 
expresses reelin to the mammal. In still other embodiments, 
the amount of APP in a manimal is altered by administration 
of an anti-APP antibody, a drug that alters APP levels, a vector 
that expresses APP, or the APP protein to the mammal. In still 
other embodiments, reelin can be administered before, after 
or concurrently with the more developmentally potent cells of 
the invention. Similarly, in other embodiments, anti-sAPP 
antibody or s-APP (secreted APP) can be administered 
before, after or concurrently with the more developmentally 
potent cells of the invention. In related embodiments, the 
invention provides methods of altering the migration of 
endogenous or exogenous multipotent stem cells in a mam-
mal by altering the amount or binding affinity of APP or reelin 
In the practice of this aspect of the invention, the phenotype 
of the more developmentally potent cell is changed when it 
differentiates into a terminally-differentiated cell. Thus, the 
invention provides methods for changing a first phenotype of 
a more developmentally potent cell into a second phenotype 
ofless developmentally potent, more preferably a terminally-
differentiated cell. The method further provides a method for 
changing a developmental potential phenotype of a cell, com-
prising the steps of contacting a cell of a first developmental 
potential phenotype with an effective amount of substituted 
deoxynucleotide or deoxynucleoside for an effective period 
that causes the cell to change into a second developmental 
potential phenotype distinct from the first developmental 
potential phenotype, wherein said second developmental 
potential phenotype is determined by the environment sur-
rounding the substituted deoxynucleotide or deoxynucleo-
side contacted cell. In certain embodiments, the cell of a first 
developmental potential phenotype can be a stem cell. In 
other embodiments, the cell of a first developmental potential 
phenotype can be a hematopoietic stem cell, a neural stem 
cell, an epithelial stem cell, an epidermal stem cell, a retinal 
50 receptor in the mammal. Similarly, the invention provides a 
method of altering the differentiation of endogenous or exog-
enous multipotent stem cells in a mammal by altering the 
amount or binding affinity of APP receptor in the mammal. 
In another aspect, the invention provides a method of mak-
55 ing a differentiated cell-specific product comprising the steps 
of differentiating the more developmentally potent cells of 
the invention, in the presence of an effective amount of factors 
known to induce differentiation of the desired cell type and 
isolating the desired differentiated cell-specific product. In 
60 another embodiment, the invention provides a method of 
making an undifferentiated cell-specific product comprising 
the steps of propagating the more developmentally potent 
cells of the invention according to the methods of the inven-
tion and isolating the desired undifferentiated cell-specific 
65 product. 
Thus, the invention advantageously provides novel mam-
malian multipotent stem cells, pharmaceutical compositions 
US 7,635,467 B2 
9 
thereof, and methods of preparing and administering the 
cells. The invention also advantageously provides methods of 
altering the migration and/or differentiation of multipotent 
stem cells through the alteration of APP and reeling levels. 
Further, the invention advantageously provides methods of 5 
utilizing the methods and cells of the invention to produce 
biochemical products. 
10 
entiated into bIII-tubulin positive cells (green), in CAI pyra-
midal cell layer. These bIII-tubulin positive cells have BrdU 
positive nuclei (red), indicating that these cells originated 
from transplanted cells. In contrast, host cell nuclei counter 
stained with DAPI (blue) are not bIII-tubulin positive. (e) In 
the dentate gyrus many fibers were bIII-tubulin positive in 
addition to the bIII-tubulin positive cells (green) and GFAP 
positive cells (red). (f) bIII-tubulin positive cells (green) and 
GFAP positive cells (red) were found in layer IV and layer III, 
Specific embodiments of the present invention will become 
evident from the following more detailed description of cer-
tain preferred embodiments and the claims. 10 respectively. Such a layer of astrocytes were not observed in 
normal rats without MNSC transplantation. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 
publication with color drawing(s) will be provided by the 
Office upon request and payment of the necessary fee, pur-
suant to 37 C.F.R. §1.84. 
FIG. 5 shows co-localization of bIII-tubulin (a neuronal 
marker) and BrdU immunoreactivity in the same cells. (a-c) 
Three different planes of the same microscopic view. The bIII 
15 -tubulin positive cells (green) show BrdU positive nuclei 
(red) indicating that these cells are derived from transplanted 
NSCs. 
FIG. 1 shows a phase contrast photomicrograph of a float-
ing, aggregated cluster of cells, characteristic of certain 20 
embodiments of the cells of the invention. 
FIG. 2 shows the effect of MNSC transplantation on 
memory score in the Morris water maze test. (a) Individual 
memory score before and after transplantation shows 
improvement in the majority of the animals. Blue: Aged 25 
memory impaired animals, Green: Aged memory unimpaired 
animals, Red: Matured animals. (b) Mean of memory score in 
each animal group before (narrow striped bar) and after 
(black bar) MNSCs transplantation shows a significant 
improvement in aged memory impaired and young animals. 30 
The animals that received vehicle injection do not show sig-
nificant difference in memory score between before (wide 
striped bar) and after (hatched) the injection. 
FIG. 3 shows differentiation ofMeSCs into retinal cells in 
vivo. All nuclei were counterstained by DAPI (blue). (a) 35 
Typical immunocytochemistry of retinal sections 4 weeks 
after a lesion and transplantation of MeSC of the invention 
(xi 00). The section was double-immunofluorescence stained 
with BrdU (red) and op sin (green) markers for donor cells and 
photoreceptor cells, respectively. MeSCs of the invention 40 
migrated into damaged area of the retinal tissue. A higher 
magnification (b, x400) shows that these migrating MeSCs 
also show cytosolic expression of op sin. ( c) Typical in situ 
hybridization histochemistry (xlOO) for human opsin gene 
expression using human-specific opsin sequence riboprobes 45 
(green). Incorporation ofhuman opsin positive cells to the rat 
retinal tissue is observed. 
FIG. 4 shows typical fluorescent immunohistochemical 
photomicrographs of aged rat brain 30 days after MNSCs 
transplantation. bIII-tubulin and GFAP immunoreactivity 50 
were used as markers for neuron and glia, respectively. (a) 
MNSCs of the invention migrated into the cortex and differ-
entiated into neurons as indicated by the bIII-tubulin positive 
cells (green), which have morphologies typical of pyramidal 
cells in layer IV and V of the parietal cortex. Apical dendrites 55 
were pointed towards to the edge of the cortex. Since the 
MNSCs were pre-treated with BrdU, the transplanted cells 
have BrdU positive nuclei (red). Contrarily, the host, cell's 
nuclei are counter stained with DAPI (blue). Many cells hav-
ing BrdU positive nuclei are observed with bIII-tubulin 60 
immunoreactivity in layer II and without bIII-tubulin immu-
noreactivity in layer III. (b, c) Higher magnification of the 
parietal cortex in cortex layer IV: All the bIII-tubulin immu-
noreactive (green) positive cells show BrdU (red) positive 
nuclei while many other host cell's nuclei are stained with 65 
only DAPI (blue). MNSCs tend to have largernuclei than host 
cells. ( d) MNSCs migrated into the hippocampus and differ-
FIG. 6(I) shows the immunohistochemistry of differenti-
ated human MNSCs using antibodies against bIII-tubulin (a) 
and glial fibrillary acidic protein (GFAP) (b ). FIG. 6(II) 
shows the differentiation of MNSCs in the co-culture with 
oxidatively damaged SH-Sy5 human neuroblastoma: (from 
left to right) light gray bars=control (0.0 µM H20 2 ); medium 
gray bars=low H20 2 (0.01 µM); dark gray bars=medium 
H2 0 2 (0.03 µM); black bars=high H20 2 (0.1 µM). 
FIG. 7 shows spontaneous differentiation of MNSCs in 
serum-free basal media. Mixed populations of differentiating 
cells are coronally migrating outward from a cluster of cells 
located on the top of the picture. 
FIG. 8 shows fluorescent immunocytochemistry of differ-
entiated human MNSCs (a) and MeSCs (b) of the invention. 
bIII-tubulin (green) and GFAP (red) immunoreactivity indi-
cate neuronal and glial differentiation, respectively. Nuclei 
counter-staining with DAPI is shown in blue. 
FIG. 9 shows typical fluorescent immunohistochemical 
photomicrographs in rat brain 4-6 weeks after transplantation 
of more developmentally potent MeSCs of the invention. 
bIII-tubulin immunoreactivity was used as a neuronal marker. 
Since MeSCs were treated with BrdU before transplantation, 
transplanted cells have BrdU positive nuclei (red). MeSCs 
migrated into the cortex and differentiated into neurons as 
indicated by the bIII-tubulin positive cells (green), which 
have morphologies typical of pyramidal cells (a, b ). All the 
human specific bIII-tubulin (green) positive cells show BrdU 
(red) positive nuclei while many other host cell nuclei are 
stained with only DAPI (blue). Apical dendrites were wavy 
compared with the neurons differentiated from MNSCs but 
pointed towards to the edge of the cortex. MeSCs tend to have 
larger nuclei than host cells. MeSCs migrated into the hip-
pocampus and differentiated into bIII-tubulin positive cells 
(green), in CAI pyramidal cell layer ( c-h). These bIII-tubulin 
positive cells have BrdU positive nuclei (red), indicating that 
these cells originated from transplanted cells. In contrast, host 
cell nuclei counter stained with DAPI (blue) are not bIII-
tubulin positive. At four weeks post transplantation ( c,d), the 
bIII-tubulin positive cells show bipolar neuronal morphology 
and may still be migrating to the pyramidal cell line. At 5 
weeks post transplantation, some of the cells have already 
reached the pyramidal cell line and have started to change 
morphologies. At six weeks post transplantation (g,h), the 
cells start to show pyramidal cell like morphologies. 
FIG.10 shows differentiation ofMeSCs into retinal cells in 
vivo. All nuclei were counterstained by DAPI (blue). (a) 
Typical immunocytochemistry of retinal sections 4 weeks 
after a lesion and transplantation of MeSC of the invention 
(xi 00). The section was double-immunofluorescence stained 
with BrdU (red) and ops in (green) markers for donor cells and 
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photoreceptor cells, respectively. MeSCs of the invention 
migrated into damaged area of the retinal tissue. A higher 
magnification (b, x400) shows that these migrating MeSCs 
also show cytosolic expression of op sin. ( c) Typical in situ 
hybridization histochemistry (xlOO) for human opsin gene 5 
expression using human-specific opsin sequence riboprobes 
(green). Incorporation ofhuman opsin positive cells to the rat 
retinal tissue is observed. 
FIG. 11 shows effect ofBrdU on restriction enzyme diges-
tion of genomic DNA extracted from human MeSCs. BrdU 10 
prevents methylation-sensitive restriction enzyme digestion 
of DNA in a dose-dependent mamier, indicating that BrdU 
treatment of MeSCs increased DNA methylation sites in the 
genomic DNA. 
FIG. 12 shows increased GFAP immunoreactivity in the 15 
nucleus basalis magnocellularis (NBM) 4 weeks after saporin 
lesion. Green: GFAP; Blue: DAPI. 
FIG. 13 shows choline acetyltransferase (ChAT) immu-
noreactivity in BrdU positive cells in the lesion site indicating 
replacement of lesioned cells by the transplanted cells of the 20 
invention (a-c; Green: ChAT; Red: BrdU; Blue: DAPI) and 
ChAT immunoreactivity in human nuclei positive cells in the 
lesion site ( d; Green: ChAT; Red: human nuclei; Blue: DAPI). 
FIG. 14 shows human nuclei immunoreactivity-positive 
cells that were observed in the lesion area. Red: human 25 
nuclei; Blue: DAPI. 
FIG. 15 shows GFAP and human nuclei immunoreactivity 
in the lesion site. Green: GFAP; Red: human nuclei; Blue: 
DAPI. 
12 
control animal in the CAI pyramidal cell layer. Though the 
pyramidal cell layer is not particularly clear in this figure. ( d) 
A few GFAP positive human MNSCs (brown) were found in 
the cortex. ( e) A different morphology ofbIII-tubulin (green) 
positive cells with BrdU positive nuclei (red) in the cortex. (f) 
Chain migration of reelin (green) positive cells in the cortex. 
FIG. 22 shows neuronal counts of BrdU-positive cells in 
heterozygous (reeler ( +/-), homozygous (reeler (-/-) and 
wild-type mice in the hippocampus, olfactory bulb, and SVZ. 
Significant reduction of the stem cell population was 
observed in the hippocampus (p<0.001) and olfactory bulb 
(p<0.01 ), but not in the SVZ of reeler ( +/-) and reeler (-/-) 
mice compared with wild-type mice by Fisher's Protected 
LSD post hoc analysis after ANOVA. 
FIG. 23 shows stem cells isolated from adult mice. (a) 
During in vitro expansion, the stem cells formed a cluster of 
multiple cells similar to those seen with NSCs. (b) The stem 
cells differentiated into bIII-tubulin (green) and GFAP posi-
tive cells (red), indicating multipotency of these cells. 
FIG. 24 shows that the human MNSCs were undergoing a 
much greater degree of apoptotic cell death (yellow) during 
differentiation in a serum-free unsupplemented medium (a) 
when compared to serum differentiation (b ). The Fluorescein 
Apoptosis Detection System (Promega, Madison, Wis.) was 
used to assay the DNA fragmentation ofHNSCs at 3 DIV. All 
the nuclei of HNSCs were counterstained by propidium 
iodide (red) and the DNA fragmentation-positive cells were 
stained in green. 
FIG. 25 shows time-lapse video microscopy monitoring 
FIG. 16 shows expression ofreelin, a3-integrin and Dab-I 
in the human MNSCs. (a) reelin immunoreactivity was 
mainly detected in the neuronal like cells (green), while 
GFAP positive cells (red) also possess reelin immunoreactiv-
ity. (b) a3-integrin (green) expresses specifically in the neu-
ron-like cell, while Dab-I (red) express in most of the cells. 
( c) Dab- I immunoreactivity (red) is highly localized in the 
nuclei. (d) In side of the cluster ofMNSCs, we also detected 
reelin immunoreactivity (green). 
30 the characteristics ofMNSC differentiation in cultures plated 
in a serum-free unsupplemented medium at 2 DIV. The dif-
ferentiating MNSCs (arrow) migrate away from the cluster of 
cells (a). Interestingly, these cells are extending processes 
onto nearby the morphologically shrunken, apparently apop-
FIG. 17 shows an electron microscopic image showed that 
a3-integrin immunoreactivity was localized on the membrane 
of the cells. 
FIG. 18 shows Western blot analysis of (a) reelin, (b) 
a3-integrin and (c) DAB-1. 
FIG. 19 shows reelin expression in embryonic stem cells. 
Reelin immunoreactivity is showed in green and the nuclei 
were stained with DAPI (blue). 
35 totic, cells (b ), followed by retraction of the processes ( c ). The 
processes appeared to be attached to the apoptotic cells ( d), 
which were drawn back into the cluster of cells ( e ). The 
response of differentiating NSCs to the apoptotic cells further 
suggested that some component( s) of the apoptotic cells serve 
40 as factors capable of influencing the physiological activity of 
differentiating NSCs. 
FIG. 26 shows that apoptotic cells in the serum-free differ-
entiation conditions were APP immunopositive. All the 
nuclei ofHNSCs were counter-stained by DAPI (a, blue). The 
45 TUNEL signal (b, green) and immunoreactivity for APP rec-
ognized by the 22Cl I monoclonal antibody (which recog-
nized the N-terminal end of APP) (c, red) are co-localized in 
the cells of shrunken morphology in the serum-free differen-
FIG. 20 shows immunohistochemistry of control mouse 
brain after human MNSC transplantation. (a) Human MNSCs 
migrated into the cortex and differentiated into neurons as 
indicated by bIII-tubulin positive cells (green). (b) Under 50 
higher magnification, neuronally differentiated cells (green) 
with BrdU positive nuclei (red) have morphologies typical of 
pyramidal cells. ( c) Human MNSCs migrated into the hip-
pocampus and differentiated into bIII-tubulin positive cells 
(green) with BrdU positive nuclei (red), having morphologies 55 
typical of pyramidal cells in CAI pyramidal cell layer. ( d) A 
layer of GF AP positive human MNSCs (brown) were found in 
the cortex. (e) Double-immunostaining revealed association 
tiation condition ( d). 
FIG. 27 shows that treatment of human MNSCs in the 
non-serum unsupplemented media with the 22Cl I mono-
clonal antibody recognizing the N-terminal end of APP dose-
dependently inhibited their differentiation. The panels show 
typical morphology of human MNSCs when treated with 
22Cl I (a; control, b; 125 µg/ml, c; 250 µg/ml, d; 500 µg/ml 
22Cll) at 3DIV. 
FIG. 28 shows that the treatment of the human MNSCs in 
culture with the recombinant secreted type of amyloid pre-
cursor protein (sAPP) for 5 days dose-dependently increased 
60 the differentiation of human MNSCs under serum-free 
of the GFAP positive cells (red) with the bIII-tubulin positive 
cells in the cortex. 
FIG. 21 shows immunohistochemistry of reeler mouse 
brain after human MNSC transplantation. (a) Few bIII-tubu-
lin positive cells (green) were detected. (b) Under higher 
magnification, we found one group ofBrdU positive cells on 
the side of the injection. ( c) Differentiation of human MNSCs 
into bIII-tubulin positive cells in the hippocampus (green), 
having different morphologies than the cells found in the 
unsupplemented condition (a; control, b; 25 ng/ml, c; 50 
ng/ml and d; 100 ng/ml). 
FIG. 29 shows that the cell population of sAPP-treated 
human MNSCs at 5 DIV in serum-free differentiation condi-
65 tion was characterized by double immunofluorescence stain-
ing with GFAP (red) and bIII-tubulin (green), which are 
markers for astrocytes and neurons respectively. All nuclei 
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were counter stained by DAPI (blue). The panels show typical 
morphology and differentiation pattern of human MNSCs 
treated with (a); control, (b ); 25 ng/ml, (c); 50 ng/ml and (d); 
100 ng/ml of sAPP. At low doses of sAPP (e.g., 25 ng/ml), 
increased glial (red) and neuronal (green) differentiation was 5 
observed as compared to the control. With higher doses of 
sAPP, many glialy differentiated human MNSCs (red) were 
observed. 
larly more developmentally potent cells that can be adminis-
tered to an animal in need thereof. 
As disclosed in further detail herein, the inventive methods 
provide for culturing less developmentally potent cells 
obtained, inter alia, from somatic tissue sources, and produc-
ing more developmentally potent, cells therefrom. In one 
aspect, this effect is achieved by culturing the less develop-
mentally potent cells in the presence of a substituted deoxy-FIG. 30 shows the quantitative population analysis of the 
each differentiation type. Cells immunostainedforGFAP and 10 
bIII-tubulin were tallied versus total cell numbers of DAPI-
nucleotide or deoxynucleoside compound. Exemplary sub-
stituted deoxynucleotide or deoxynucleoside compounds as 
provided by the invention include but are not limited to halo-
gen-substituted (halo-substituted) deoxynucleotides or 
deoxynucleosides, such as, for example, bromodeoxyuridine, 
labeled nuclei. All data values reported are expressed as mean 
percentages (±S.E.M.). One Factor AN OVA followed by post 
hoc analysis (Student- Newman-Keuls) was used to demon-
strate statistically significant differences between experimen-
tal groups and control(*: p<0.01). 
FIG. 31 shows that human MNSCs transfected with mam-
malian expression vectors containing genes for either wild 
type APP (wtAPP) that were differentiated under serum-free 
unsupplemented conditions displayed a significantly higher 
level of glial differentiation as compared to human MNSCs 
transfected with the vector alone at 5DIV. Pictures show 
double immunofluorescence staining with GFAP (red) and 
bIII-tubulin (green), which are markers for astrocytes and 
neurons respectively. All nuclei were counter stained by 
DAPI (blue). 
15 iododeoxyuridine, bromodeoxyguanosine, iododeoxycy-
tosine as well as alkyl-substituted species such as, for 
example, methyldeoxythymidine. A most preferred species is 
bromodeoxyuridine (BrdU). BrdU is a thymidine analog that 
was originally produced for chemotherapy. It is known to 
20 regulate gene expression and cellular differentiation of some 
cell types. Since BrdU and other substituted deoxynucleotide 
or deoxynucleoside compounds, are incorporated into the 
nuclei of proliferating cells and are easy to detect by immu-
nostaining, it has been used for detecting proliferating cells, 
25 such as stem cells; however, its biological effects on stem 
cells has not been appreciated, understood or disclosed in the 
art. FIG. 32 shows thatthehumanMNSCs transplanted to APP 
knockout mouse brain show less migration and differentia-
tion as compared to cells transplanted into wild type control 
mice. Human MNSCs were treated with BrdU before the 30 
While adult stem cells continue to possess some multipo-
tency, adult stem cells are limited by their tissue-specific 
character. As an example, human NSCs spontaneously differ-
entiate into brain cells under basal media conditions, but unilateral ventricle injection to aid in the discrimination from 
host cells. Brain tissues were immunoblotted for bIII-tubulin, 
GFAP, and BrdU 4 weeks post-injection. In the wild type 
mice, the immunopositive cells for BrdU (red) and bIII-tubu-
lin (green) distributed bilaterally in the singular and parietal 
cortexes (a) and pyramidal layer of the hippocampus (c), 
indicating neuronal differentiation of transplanted human 
MNSCs. The human MNSCs also differentiated into GFAP-
immunopositive cells (red) that localized with the bIII tubulin 
(green) stained neuronal fibers of layer III in the cortex ( e ). 
The differentiation and distribution patterns of the trans-
planted human MNSCs were similar to what we found in our 
previous transplantation study with rats. In the APP knockout 
mice, those bIII-tubulin positive cells (green) with BrdU posi-
tive nuclei (red), derived from the transplanted human 
MNSCs, that were seen in the cortex were scarcely distributed 
and lacked apical dendrites (b ). In the hippocampus, bIII-
tubulin (green) and BrdU (red) immunopositive cells had 
quite similar distribution and structure to the cells found in the 
wild type mice ( d,f). 
FIG. 33 shows a comparison of endogenous NSC popula-
tions in APP knockout and wild-type mice (xlOO). BrdU 
incorporated into the nuclei of proliferating cells was 
detected by fluorescent immunohistochemistry (red), and all 
the nuclei were counter-stained with DAPI (blue). The upper 
panels show a dramatically decreased population of stem 
cells in the hippocampus of APP knockout mouse (a) com-
pared with wild-type mouse (b). The lower panels show a 
similar population of stem cells in the subventricular zone 
(SVZ) of APP-knockout mice (c) compared with wild-type 
mice (d). 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
This invention provides more developmentally potent cells 
capable of differentiating in a tissue specific mamier, particu-
MeSCs are essentially unable to spontaneously differentiate 
into neural cells without the addition of certain factors; in the 
context of the invention, such cells are less developmentally 
35 potent than cells that could differentiate into cells of two or 
more different lineages. These results indicate that each kind 
of tissue-specific stem cell contains specific information that 
allows it to become a special type of cell, i.e., they are par-
tially committed to become a particular type of cell in a 
40 tissue-specific manner (i.e., less developmentally potent). To 
overcome this barrier of stem cell lineage and make cells that 
are more developmentally potent, alterations to the cells and 
their environment are necessary. The invention relates to 
methods of making more developmentally potent cells from 
45 less developmentally potent cells, as well as methods of treat-
ment and use of the more developmentally potent cells, and 
the more developmentally potent cells themselves. As an 
example, the invention relates to the treatment of easily iso-
lated and abundant stem cells like mesenchymal stem cells 
50 (i.e., a less developmentally potent cell) such that they are no 
longer constrained to differentiate into only mesenchymal-
lineage cells such as osteocytes and chrondrocytes, among 
others. Treated according to the invention, the less develop-
mentally potent mesenchymal stem cell becomes a more 
55 developmentally potent cell capable of differentiation into, 
for example, neural-lineage cells. The present invention also 
enables the use of autologous transplantation, which elimi-
nates possibility of an immune reaction against a transplant of 
the more developmentally potent cells of the invention. For 
60 example, a patient's mesenchymal stem cells could be iso-
lated, treated according to the methods of the invention, and 
transplanted back into the same patient to differentiate in a 
tissue-specific mamier regardless the transplantation site, be 
it brain, eye, muscle, etc. Thus, the present invention provides 
65 a means to treat neurological and corporal deficits without the 
problems associated withheterologous transplants from adult 
or fetal sources. 
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As used herein, the terms "multipotent neural stem cells 
(MNSCs)," "neural stem cells (NSCs)" and "neural progeni-
tor cells (NPCs)" refer to undifferentiated, multipotent cells 
of the CNS. Such terms are commonly used in the scientific 
literature. MNSCs can differentiate into tissue-specific cell 
types, for example astrocytes, oligodendrocytes, and neurons 
when transplanted in the brain. MNSCs of the invention are 
distinguished from natural MNSCs by their adaptation for 
proliferation, migration and differentiation in mammalian 
host tissue when introduced thereto. 10 
As used herein, a "less developmentally potent cell" is a 
cell that is capable oflimited multi-lineage differentiation or 
capable of single-lineage, tissue-specific differentiation, for 
example, an untreated riesenchymal stem cell can differenti-
ate into, inter alia, osteocytes and chrondrocytes, i.e., cells of 15 
mesenchymal lineage, but has only limited ability to differ-
entiate into cells of other lineages (e.g., neural lineage.). 
16 
herein, can be between to 10 days, or more preferably 
between about 1 to 7 days, or even more preferably between 
about 2 to 5 days. 
The term "pharmaceutically acceptable carrier" or "physi-
ologically acceptable carrier" as used herein refers to one or 
more formulation materials suitable for accomplishing or 
enhancing the successful delivery of the pharmaceutical com-
position of more developmentally potent cells prepared and 
delivered according to the invention. 
As used herein, "ameliorating the effects caused by age, 
physical and biological trauma and degenerative disease" and 
the like refers to the diminution of the detrimental effects of 
damaged or degenerated tissue due to the use or administra-
tion of an effective amount of the more developmentally 
potent cells of the invention, or pharmaceutical preparations 
thereof, to the affected, damaged or degenerated tissue, 
wherein the stem cells can differentiate in a manner appro-
priate for the host tissue and enable the replacement of dam-
aged cells, repair of damages tissue and reduction of struc-
tural or functional loss. For example, the neurological effects 
of events, diseases or processes that result in the loss of some 
degree of brain function or proper brain function. Such ame-
lioration is affected through the administration to the animal 
of an effective amount of the more developmentally potent 
cells or pharmaceutical compositions thereof of the inven-
tion. 
The invention also provides pharmaceutical compositions 
of the more developmentally potent cells of the invention and 
methods of delivery into the brain and other tissues thereof. 
As used herein, a "more developmentally potent cell" is a 
cell that is readily capable of differentiating into a greater 
variety of cell types than its corresponding less developmen- 20 
tally potent cell. For example, a mesenchymal stem cell can 
readily differentiate into osteocytes and chrondrocytes but 
has only limited ability to differentiate into neural or retinal 
lineage cells (i.e., it is a less developmentally potent cell in 
this context). Mesenchymal stem cells treated according to 25 
the methods of the invention become more developmentally 
potent because they can readily differentiate into, for 
example, mesenchymal-lineage and neural-lineage cell 
types; the plasticity of the cells is increased when treated 
according to the methods of the invention. 30 The invention also provides methods of abating or remedying 
the effects of brain or other tissue disease or dysfunction 
caused by the loss of, or loss of appropriate, brain or other 
tissue function due to age, physical or biological trauma or 
One or more of the more developmentally potent cells of 
the invention can propagate as separate cells and can also 
form a cluster of two or more cells. The clusters can comprise 
the progeny of a single more developmentally potent cell or 
clusters of primary cells. 
neurodegenerative disease. 
35 
As used herein, the terms "effective amount" and "thera-
peutically effective amount" each refer to the amount of 
reagent used to support the desired activity. In the case of 
more developmentally potent cells prepared and delivered 
according to the invention, an effective amount is an amount 40 
necessary to support an observable level of one or more 
biological activities of MSC as set forth herein. Regarding 
substituted deoxynucleotide or deoxynucleoside compounds, 
Cells can be obtained in many ways and from many tissues, 
for example, from donor tissue by dissociation of individual 
cells from the connecting extracellular matrix of the tissue or 
from commercial sources ofNSCs (e.g., Bio Whittaker, Walk-
ersville, Md., CC-25 99 ). For certain neural stem cell embodi-
ments of the more developmentally potent cells of the inven-
tion, tissue from brain is removed using sterile procedures, 
and the cells are dissociated using any method known in the 
art including treatment with enzymes such as trypsin, colla-
genase and the like, or by using physical methods of disso-an effective amount can be between about 10 nanomolar and 
100 micromolar, or more preferably between about 2 and 50 
micromolar, or even more preferably about 10 micromolar. 
Regarding the method of making a retinal cell from the cells 
of the invention, an effective amount ofTGF-b3, CNTF and 
IGF can be between about 1 ng/ml to 1 ug/ml, or more 
preferably between about 5 ng/ml to 500 ng/ml, or even more 
preferably between about 10 ng/ml to 100 ng/ml, or even 
more preferably about 50 ng/ml. 
An "effective period" as used herein refers to the time 
period necessary for the reagents and cells of the invention to 
accomplish their specified activities. For example, less devel-
opmentally potent cells can be contacted with a substituted 
deoxynucleotide or deoxynucleoside compound for an effec-
tive period to make them more developmentally potent. An 
effective period for contact with a substituted deoxynucle-
otide or deoxynucleoside compound, as referred to herein, 
can be between 1 to 10 days, or more preferably between 
about 1 to 5 days, or even more preferably between about 2 to 
3 days. Further, cells of the invention can be contacted before 
or during differentiation with TGF-b3, CNTF, IGF, or com-
binations thereof, for an effective period to make them 
capable of differentiating into retinal cells. An effective 
period for TGF-b3, CNTF and IGF contact, as referred to 
45 ciation such as mincing or treatment with a blunt instrument. 
Dissociation of neural cells, and other multi potent stem cells, 
can be carried out in tissue culture medium; in a preferred 
embodiment, the medium for dissociation of juvenile and 
adult cells is low calcium artificial cerebral spinal fluid 
50 (aCSF) having a formula identical to aCSF (124 mM NaCl, 5 
mM KC!, 1.3 mM MgCl2 , 2 mM CaCl2 , 26 mM NaHC03 , 
and 10 mM D-glucose) except that MgCl2 is present at a 
concentration of3.2 mM and CaCl2 at a concentration of0.1 
mM. Dissociated cells are centrifuged at low speed, between 
55 200 and 2000 rpm, usually between 400 and 800 rpm, the 
suspension medium is aspirated, and the cells are then resus-
pended in culture medium. Suspension cultures are preferred 
if large numbers of undifferentiated stem cell progeny are 
desired. Cell suspensions are seeded in any receptacle 
60 capable of sustaining cells, preferably uncoated flask or a 
flask that has been treated to repel the cells, culture plates or 
roller bottles that inhibit contact-dependent stem cell differ-
entiation. 
While isolation from brain tissue is feasible, mesenchymal 
65 stem cells from bone is a particularly good source of cells for 
use in generating more developmentally potent cells for use in 
the invention because isolation techniques are well estab-
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lished in the art (having been used for decades in immune 
disorder bone marrow transplants), and such techniques can 
be performed autologously. The patient's own mesenchymal 
stem cells can be isolated, treated according to the invention 
and readministered where necessary. In contrast, autologous 
transplants using a neural cell source is not particularly fea-
sible. 
Growth of more developmentally potent cells under the 
above culture conditions induces or permits these cells to 
form undifferentiated clusters of two or more cells (shown in 
FIG. 1). These clusters are optimally grown at a density of 
approximately 50 per T75 flask in 20 mL of the growth 
medium consisting of, for example, DMEM/HAMS F12 (at 
about 3: 1; Gibco, BRL, Burlington, ON), supplemented with 
an antibiotic-antimycotic mixture (1: 100, penicillin G, strep-
tomycin sulfate, amphotericin B; Gibco ), B27 (1:50, 
GIBCO), human recombinant FGF-2 and EGF (20 ng/ml 
each, R&D Systems, Minneapolis, Minn.) and heparin (5 
µg/mL, Sigma, St. Louis, Mo.). The cultures are kept in a C02 
incubator (about 5% C02 ) at 37° C. To facilitate optimal 
growth conditions, any clusters of two or more cells are 
sectioned into quarters approximately every 14 days and fed 
18 
medium at concentrations of between about 1 fg/mL to 1 
mg/mL. Concentrations between about 1 to 100 ng/mL are 
usually sufficient. Simple titration experiments routine in the 
art are used to determine the optimal concentration of a par-
ticular growth factor for a particular cell culture. 
Cells of the invention that are proliferated in serum-free 
media should be grown in the presence ofa substituted deoxy-
nucleotide or deoxynucleoside compounds such as, for 
10 example, halogenated-deoxynucleosides like bromodeox-
yuridine (BrdU) or iododeoxyguanosine (IrdG), alkyl-substi-
tuted examples such as methyldeoxyguanosine prior to trans-
plantation into a host. The pre-transplant growth medium 
comprises the components of the long-term propagation 
15 media, but also contains an effective amount of substituted 
deoxynucleotide or deoxynucleosides for use for an effective 
period. More developmentally potent cells prepared accord-
ing to the methods of the invention are conditioned or adapted 
to proliferate, migrate and differentiate properly in the brain 
20 when transplanted into host tissue. 
by replacing 50% of the medium approximately every 4-5 
days. These conditions permit rapid and continual growth of 
NSCs, as well as the more or less developmentally potent 25 
cells of the invention, that can be expanded indefinitely while 
retaining their multipotent character. As with most eukaryotic 
cells, conditions for culturing should be as close as possible to 
physiological conditions. The pH of the culture medium 
should be close to physiological pH, preferably between pH 30 
6-8, more preferably between about pH 7 to 7 .8, with pH 7.4 
being most preferred. Physiological temperatures range 
between about 30° C. to 40° C. Cells are preferably cultured 
Cellular preparations and pharmaceutical compositions of 
the more developmentally potent cells of the invention are 
also provided herein. Pharmaceutical compositions optimally 
comprise a therapeutically effective amount of more devel-
opmentally potent cells in admixture with a pharmaceutically 
or physiologically acceptable formulation agent selected for 
suitability with the mode of administration. Acceptable for-
mulation materials preferably are nontoxic to the more devel-
opmentally potent cells and the recipients at the dosages and 
concentrations employed. 
The cellular preparations and pharmaceutical composi-
tions of the invention may contain formulation materials for 
modifying, maintaining, or preserving, for example, pH, 
osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, 
stability, rate of dissolution or release, adsorption, or penetra-
at temperatures between about 32° C. to about 38° C., and 
more preferably between about 35° C. to about 37° C. Neural 35 
stem cells (NSCs) prepared and maintained as disclosed 
herein continue to exhibit multipotent character after more 
than three years of serum-free propagation. If in vitro differ-
entiation is desired, the cells can be rep lated in culture dishes 
tion of the composition, as well as proliferation, migration 
and differentiation capacity of the more developmentally 
potent cells of the invention. Suitable formulation materials 
include, but are not limited to, amino acids (such as glycine, 
glutamine, asparagine, arginine, or lysine), antimicrobial 
compounds, antioxidants (such as ascorbic acid, sodium 
sulfite, or sodium hydrogen-sulfite), buffers (such as borate, 
bicarbonate, Tris-HCl, citrates, phosphates, or other organic 
in, for example, serum-free basal medium Eagle (BME), 40 
which contains Earle's salt and L-glutamine. The cells can be 
cultured for about 5 days in the absence of FGF-2, EGF or 
other extrinsic differentiation factors. When induced to dif-
ferentiate in this way, these cultured NSCs exhibit character-
istic morphologies of neurons or astrocytes when immuno-
histochemically stained with b-III tubulin (a neuronal cell 
marker) or glial fibrillary acidic protein (GFAP, an astrocyte 
marker). 
45 acids), bulking agents (such as mannitol or glycine), chelat-
ing agents (such as ethylenediamine tetraacetic acid 
(EDTA)), complexing agents (such as caffeine, polyvinylpyr-
rolidone, betacyclodextrin, or hydroxypropyl-beta-cyclodex-
trin), fillers, monosaccharides, disaccharides, and other car-As disclosed above, the stem cell culture medium as used in 
the invention is preferably supplemented with at least one 
proliferation-inducing growth factor. A growth factor, as 
defined herein, refers to a protein, peptide or other molecule 
having a growth, proliferative, or trophic effect on the more or 
more developmentally potent cells and/or more or more 
developmentally potent cell progeny of the invention. Growth 
factors that are used for inducing proliferation include any 
trophic factor that allows more or more developmentally 
potent cells to proliferate, including any molecule that binds 
to a receptor on the surface of the cell to exert a trophic, or 
growth-inducing effect on the cell. Exemplary proliferation-
inducing growth factors include epidermal growth factor 
(EGF), insulin-like growth factor (IGF), ciliary neurotrophic 
factor (CNTF), amphiregulin, acidic fibroblast growth factor 
(aFGF or FGF-1), basic fibroblast growth factor (bFGF or 
FGF-2), and combinations thereof. Preferred proliferation-
inducing growth factors include EGF and FGF or a combina-
tion thereof. Growth factors are usually added to the culture 
50 bohydrates (such as glucose, marmose, or dextrins ), proteins 
(such as serum albumin, gelatin, or immunoglobulins), col-
oring, flavoring and diluting agents, emulsifying agents, 
hydrophilic polymers (such as polyvinylpyrrolidone), low 
molecular weight polypeptides, salt-forming counterions 
55 (such as sodium), preservatives (such as benzalkonium chlo-
ride, benzoic acid, salicylic acid, thimerosal, phenethyl alco-
hol, methylparaben, propylparaben, chlorhexidine, sorbic 
acid, or hydrogen peroxide), solvents (such as glycerin, pro-
pylene glycol, or polyethylene glycol), sugar alcohols (such 
60 as marmitol or sorbitol), suspending agents, surfactants or 
wetting agents (such as pluronics; PEG; sorbitan esters; 
polysorbates such as polysorbate 20 or polysorbate 80; triton; 
trimethamine; lecithin; cholesterol or tyloxapal), stability 
enhancing agents (such as sucrose or sorbitol), tonicity 
65 enhancing agents (such as alkali metal halides-preferably 
sodium or potassium chloride--or mannitol sorbitol), deliv-
ery vehicles, diluents, excipients and/ or pharmaceutical ad ju-
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vants. See REMINGTON'S PHARMACEUTICAL SCI-
ENCES (18th Ed., A. R. Gennaro, ed., Mack Publishing 
Company 1990). 
The primary vehicle or carrier in a pharmaceutical compo-
sition may be either aqueous or non-aqueous in nature. For 
example, a suitable vehicle or carrier for injection may be 
water, physiological saline solution, or artificial cerebrospi-
nal fluid. Optimal pharmaceutical compositions will be deter-
mined by a skilled artisan depending upon, for example, the 
intended route of administration, delivery format, desired 
dosage and recipient tissue. See, e.g., REMINGTON'S 
PHARMACEUTICAL SCIENCES, supra. Such composi-
tions may influence the physical state, stability, and effective-
ness of the MNSC composition. 
20 
the more developmentally potent cells of the invention are 
transplanted intraventricularly. Further, while the transplan-
tation of one or more separate more developmentally potent 
cells is efficacious, the more developmentally potent cells of 
the invention are preferably transplanted in the form of clus-
ters of two or more cells via a surgical procedure or injection 
using a syringe large enough to leave the clusters substan-
tially intact. The results disclosed in the Examples below 
indicate that ventricular delivery of more developmentally 
10 potent cells of the invention in the form of a cluster of two or 
more cells can result in migration to the area of damage in the 
brain and proper neuronal differentiation. Another benefit of 
intraventricular injection is less tissue destruction, resulting 
in less localized recruitment of immune cells by the host. This 
15 is evidenced by the lack of ventricular distortion, tumor for-
mation, and increased host astrocyte staining without any 
The invention provides methods of delivery and transplan-
tation of the more developmentally potent cells of the inven-
tion to ameliorate the effects of age, physical and biological 
trauma and degenerative disease on the brain or central ner-
vous system of an animal, as well as other tissues such as, for 
example, retinal tissue. It is well recognized in the art that 20 
transplantation of tissue into the CNS offers the potential for 
treatment of neurodegenerative disorders and CNS damage 
due to injury. Transplantation of new cells into the damaged 
CNS has the potential to repair damaged circuitries and pro-
vide neurotransmitters thereby restoring neurological func- 25 
tion. It is also recognized in the art that transplantation into 
other tissue, such as eye tissue, offers the potential for treat-
ment of degenerative disorders and tissue damage due to 
injury. As disclosed herein, the invention provides methods 
for generating more developmentally potent cells adapted for 30 
proliferation, migration and differentiation in mammalian 
tissue when introduced thereto. The use of more developmen-
tally potent cells in the treatment of neurological disorders 
and CNS damage, as well as the use of more developmentally 
potent cells in the treatment of other tissue damage or degen- 35 
eration, can be demonstrated by the use of established animal 
models known in the art. 
immunosuppression. 
The method of delivery of the more developmentally 
potent cells of the invention to the brain can be essentially 
duplicated for other immunoprivileged tissue such as, for 
example, the eye. Delivery of one or more separate or two or 
more of the more developmentally potent cells in the form of 
a cluster via injection using a syringe large enough to leave 
the any cluster of two or more cells that is present substan-
tially intact can result in migration to the area of damage in the 
eye and proper tissue-specific differentiation. 
There are examples in the art of intra-tissue injection 
(brain) of dissociated and partially differentiated NSCs (see, 
e.g., Benninger et al., 2000, Brain Pathol. 10: 330-341; 
Blakemore et al., 2000, Cell Transplant. 9: 289-294; Rosser et 
al., 2000, Eur. J. Neurosci. 12: 2405-2413; Rubio et al., 2000, 
Mal. Cell. Neurosci. 16: 1-13). Further, the dissociation of 
NSC neurospheres is known to cause immediate senescence 
of NSCs and increase the vulnerability of NSCs in culture. 
See, e.g., Svendsen et al., 1998, J. Neurosci. Methods 85: 
141-15 2. Some aspects of the instant invention preferentially 
employ injection of clusters of two or more cells, but the more 
developmentally potent cells of the invention appear to 
migrate and differentiate appropriately when transplanted in 
More developmentally potent cells of the invention can be 
administered to an animal with abnormal or degenerative 
symptoms obtained in any manner, including those obtained 
as a result of age, physical or biological trauma, or neurode-
generative disease and the like, or animal models created by 
man using recombinant genetic techniques, such as trans-
genic and "gene knockout" animals. 
Recipients of the more developmentally potent cells of the 
invention can be immunosuppressed, either through the use of 
immunosuppressive drugs such as cyclosporin, or through 
local immunosuppression strategies employing locally 
applied immunosuppressants, but such immunosuppression 
need not necessarily be a prerequisite in certain immunoprivi-
leged tissues such as, for example, brain and eye tissues. In 
certain embodiments, the delivery method of the invention 
can cause less localized tissue damage to the site of cell 
damage or malfunction than existing methods of delivery. 
More developmentally potent cells of the invention can be 
prepared from the recipient's own tissue. In such instances, 
the progeny of the more developmentally potent cells can be 
generated from dissociated or isolated tissue and proliferated 
in vitro using the methods described herein. In the case of 
mesenchymal stem cells (MeSCs ), progeny can be generated 
from MeSCs isolated from, for example, bone marrow. Upon 
suitable expansion of cell numbers, the stem cells of the 
invention can be harvested and readied for administration into 
the recipient's affected tissue. 
There are significant differences in the method of delivery 
to the brain of the more developmentally potent cells com-
pared to the prior art. One exemplary difference is as follows: 
40 non-cluster from as well. As provided by this invention, intra-
ventricular transplantation provides an alternative route to the 
site-specific injection disclosed in the prior art. Using intra-
ventricular transplantation, grafted cells can gain access to 
various structures by the flow of CSF, and transplantation of 
45 more developmentally potent cells of the invention in cluster 
form can act to prevent premature differentiation at inappro-
priate anatomical sites in the brain and central nervous sys-
tem. Regarding the eye, intraocular administration of clusters 
of two or more cells, for example into the vitreous fluid, 
50 allows the more developmentally potent cells of the invention 
to migrate to the area of degeneration or injury and differen-
tiate appropriately. 
Delivery of more developmentally potent cells of the 
invention into other, non-immunoprivileged tissues can also 
55 be carried out, particularly when the more developmentally 
potent cells are autologous to the recipient. 
Functional integration of the graft into the host's neural 
tissue can be assessed by examining the effectiveness of 
grafts on restoring various functions, including but not lim-
60 ited to tests for endocrine, motor, cognitive and sensory func-
tions. Useful motor tests include tests that quantitate rota-
tional movement away from the degenerated side of the brain, 
and tests that quantitate slowness of movement, balance, 
coordination, akinesia or lack of movement, rigidity and 
65 tremors. Cognitive tests include tests of the ability to perform 
everyday tasks, as well as various memory tests, including 
maze performance such as the Morris water maze perfor-
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mance. For example, using the cells and methods of the 
invention, more developmentally potent cells injected into the 
ventricle of 24 month-old rats after in vitro expansion dis-
played extensive and positional incorporation into the aged 
host brain with improvement of cognitive score (FIG. 2), as 
assessed by the Morris water maze after 4 weeks of the 
transplantation. Results of the experiments disclosed herein 
indicate that the aged brain is capable of providing the nec-
essary environment for more developmentally potent cells of 
the invention to retain their multipotent status and demon- 10 
strate the potential for neuroreplacement therapies in age 
associated neurodegenerative disease. 
Functional integration of the graft into the host's other 
tissue can be assessed by examining the effectiveness of 
grafts on restoring various functions specific to the injured or 15 
degenerated tissue, for example improvement in sight for 
transplantation of stem cells of the invention to the eye. 
Regarding the eye, using the cells and methods of the inven-
tion, more developmentally potent cells of the invention 
injected into the vitreous cavity of rat eyes after in vitro 20 
expansion displayed extensive and positional incorporation 
into the host eye tissue (FIG. 3) 4 weeks post-transplantation. 
Results of the experiments disclosed herein indicate that the 
eye, as with the brain, is capable of providing the necessary 
environment for the more developmentally potent cells of the 25 
invention to differentiate in a tissue-specific manner, and thus 
demonstrate the potential for replacement therapies in injury 
or degeneration-associated tissue damage. 
Without being restricted to any particular theory for the 
mechanism of action of the cells and methods of the inven- 30 
22 
Strong astrocyte staining was also found in the frontal 
cortex layer 3 and CA2 region of hippocampus in trans-
planted rat brains, areas where astrocytes are not normally 
present in the animal. The migration of the more developmen-
tally potent cells to the CA2 is of particular interest because 
CA2 pyramidal neurons highly express bFGF, and the expres-
sion of bFGF is up-regulated by entorhinal cortex lesions 
(see, e.g., Eckenstein et al., 1994, Biochem. Pharmacol. 47: 
103-110; Gonzalez et al., 1995, Brain Res. 701: 201-226; 
Williams et al., 1996, J. Comp. Neural. 370: 147-158). CA2 
pyramidal neurons in the host brain can express bFGF as a 
response to a reduction of synaptic transmission, an event that 
can occur during aging. Subsequently, this expressed bFGF 
can act as a signal for the transplanted more developmentally 
potent cells to respond, migrate or proliferate under the influ-
ence ofbFGF produced in the host brain after the transplan-
tation. 
The regions rich in astrocyte staining in transplanted rat 
brains are the same regions where extensively stained neu-
ronal fibers were identified (FIGS. 4a, 4d and 4e). During 
development, glial cells have many complex functions, such 
as neuronal and axonal guidance and production of trophic 
factors (see, e.g., Pundt et al., 1995, Brain Res. 695: 25-36). 
This overlapping distribution of glial and neuronal fibers 
strongly suggests that this interaction plays a pivotal role in 
survival, migration, and differentiation of transplanted more 
developmentally potent cells. 
Immunohistochemistry of transplanted rat brains reveals a 
symmetrical distribution of neurons and astrocytes at both 
sides of the host brain, indicating that the progeny of these 
more developmentally potent cells can migrate. Although 
astrocytes have been shown to migrate over long distances 
following transplantation (see, e.g., Blakemore et al., 1991, 
Trends Neurosci. 14: 323-327; Hatton et al., 1992, Glia 5: 
35 251-258; Lundberg et al., 1996, Exp. Neural. 139: 39-53), 
there is experimental evidence showing that neurons do not 
migrate as widely as glial cells (see, e.g., Fricker et al., 1999, 
J. Neurosci. 19: 5990-6005). As disclosed herein, neuronal 
precursors derived from the more developmentally potent 
tion, there are at least two explanations for the beneficial 
effects of more developmentally potent cell transplantation to 
cognitive function of the host brain as well as the beneficial 
effects of more developmentally potent cell transplantation in 
other tissues. One is replacement or augmentation. Neuronal 
circuits can be replaced or augmented by the more develop-
mentally potent cell-derived neurons. In other tissues, cells 
and cell structures can also be replaced or augmented by more 
developmentally potent cell-derived cells appropriate for that 
tissue. An alternative explanation is the trophic action of 
factors released from the transplanted more developmentally 
potent cells. Morphological analysis of rat brains trans-
planted with the more developmentally potent cells as dis-
closed herein showed extensive incorporation of the more 
developmentally potent cells and massive growth of neuronal 45 
fibers in the host brain area related to spatial memory task 
(FIGS. 4 and 5); however, the more developmentally potent 
cells may still migrate toward the damaged neurons and res-
cue them by the production of neurotrophic factors. Synergy 
between these two explanations may also exist. 
40 cells of the invention possess similar migratory capacity to 
astrocyte precursors. 
Bioreactor 
The use ofbiocatalyst for the production of useful products 
has been a part of man's history for thousands of years. Until 
this century the production of useful products from biocata-
lysts was performed in batch-type reactors (fermenters). 
Numerous newer, more efficient methods utilizing bioreac-
tors are used to regulate important growth parameters such as, 
As assessed by the Morris water maze test, improvement in 
spatial memory of more developmentally potent cell-trans-
planted animals was accompanied by incorporation of the 
more developmentally potent cells into the brain areas known 
50 for example, pH, oxygen, sterility, nutrition. The basic eco-
nomics behind biological production are two-fold: producing 
a product with greater value than the raw material it was 
derived from and producing a product that cannot be eco-
to be related to spatial memory. The post-transplant morphol- 55 
ogy of rat brain tissue indicates that functional association of 
the transplanted cells to the host brain occurs. Immunohis-
tochemical analysis revealed that the bIII-tubulin-positive 
donor-derived cells found in the cerebral cortex are charac-
terized by having dendrites pointing to the edge of the cortex 60 
whereas in the hippocampus, donor-derived neurons exhib-
ited morphologies with multiple processes and branches. 
These differential morphologies of the transplanted more 
developmentally potent cells in different brain regions indi-
cate that site-specific differentiation of the more developmen- 65 
tally potent cells occurs according to various factors present 
in each brain region. 
nomically made in any other way, in both cases for the pur-
pose of satisfying market demand. 
For bulk biochemical production, such as beer, the prin-
ciple costs are in the initial raw materials and initial capital 
costs for the production facility since millions of gallons of 
beer must be produced to obtain a reasonable return on the 
investment. It should also be noted that yields of these prod-
ucts are some of the highest of any biologically derived prod-
ucts. 
At the other extreme is high-value biochemical production, 
such as monoclonal antibody, whose largest expense is in the 
downstream processing of the product. This can occur 
because the difficulty of obtaining certain biological starting 
materials as well as other reasons such as federal regulations 
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Neural-Related 
Due to the generally low proliferation rate of manimalian 
NSCs, there is a correlation between advancing age and 
impaired brain function even in the absence of specific neu-
rodegenerative disease or physical or biological brain trauma. 
The invention provides methods for counteracting impaired 
brain function due to advancing age through the addition of 
more developmentally potent cells capable of proliferation, 
stipulating the purity of the final product if it is to be used in 
vivo. In this situation, however, the very small amount of 
product produced and the difficulty in performing the produc-
tion requires that the final product be sold at many orders of 
magnitude higher than the bulk biochemical for the same 
basic quantity. In certain circumstances, the cost of obtaining 
critical materials for biochemical production can be so pro-
hibitive that such production is not economically feasible. 
Further, some materials are simply not available at any cost, 
so methods enabling the conversion of more easily obtained 10 
( orobtainable at all) materials into that critical material can be 
extremely valuable. 
migration and differentiation in mammalian brain when 
introduced thereto. 
Physical trauma and biological trauma are additional 
causes of impaired or improper brain function. The term 
"physical trauma" denotes brain cell damage due to external 
sources such as blunt head trauma, severe concussion and the The methods of the invention make possible the conversion 
of easily obtainable less developmentally potent cells, for 
example MeSCs, to more developmentally potent cells, cells 
that can be subsequently differentiated in vitro to the desired, 
and possibly difficult to obtain, cell type for use as a bioreac-
15 like. Such physical trauma can be localized or general 
depending on the source and severity of the trauma. The term 
"biological trauma" denotes any acute brain injury that has its 
origin in a biological process, for example, stroke, aneurysm, 
epilepsy, brain tumor, hypoxia and the like. 
Another source of impaired or improper brain function is 
neurodegenerative disease. In recent years neurodegenerative 
disease has become an important concern due to an expanding 
elderly population that is at greatest risk for these disorders. 
Neurodegenerative diseases include, but are not limited 
tor for the production of proteins or products specific to the 
differentiated cell. Differentiation can be induced through 20 
exposure of the cells of the invention to growth factors and 
supplements known in the art to be important in differentia-
tion of the desired cell type. As described elsewhere herein, 
more developmentally potent cells of the invention ofMeSC 
origin were induced to differentiate in vitro to cells of retinal 
origin through exposure to TGF-b3, CNTF, or IGF-1. Further, 
using the growth conditions described herein, the more and 
less developmentally potent cells themselves can be propa-
gated long terms and used as bioreactors for production of 
proteins or products specific to those cells. The ability to 
easily isolate and propagate a potentially unlimited popula-
tion of more developmentally potent cells that have the capac-
25 Alzheimer's disease, amyotrophic lateral sclerosis (ALS), 
Parkinson's disease, Pick's disease, Huntington's disease, 
progressive supranuclear palsy, corticobasal degeneration, 
Parkinson-ALS-dementia complex, Gerstmann-Straussler-
Scheinker syndrome, Hallervorden-Spatz disease, Kufs' dis-
30 ease, Wilson's disease, multiple sclerosis (MS), late-onset 
metachromatic leukodystrophy and adrenoleukodystrophy. 
The effects of these diseases can be counteracted by admin-
istration of the more developmentally potent cells of the 
ity to terminally differentiate into a desired cell type enables 
the biochemical production of heretofore unavailable or pro- 35 
hibitively expensive cellular products. 
invention. 
There is a variety of organic brain diseases that impair 
motor or cognitive function. Degeneration in the basal gan-
glia can lead to diseases with cognitive and motor symptoms, 
depending on the exact location of the degeneration. Motor 
deficits are a common result of degeneration in the basal 
The methods of the invention also make personalized drug 
screening much more feasible, both technically and mon-
etarily. Easily obtained less developmentally potent cells 
such as MeSCs, can be treated according to the methods of the 
invention and induced to a cell type appropriate for the testing 
of a particular drug. For example, neurally differentiated cells 
have been used as an experimental system for drugs that act 
on the brain. While NSCs can be commercially obtained, they 
are not specific to any particular person and are thus useless 
for personalized drug efficacy testing. Using the methods of 
the invention, a person's less developmentally potent cells, 
for example MeSCs isolated using minimally invasive meth-
ods well established in the art, can be converted into more 
developmentally potent cells that can be differentiated into, 
for example, cells of neural origin and utilized for testing. 
Such methods can be used to determine the effect of drugs on, 
for example, expression levels of particular genes induced by 
particular drugs for a particular patient. Such information can 
be critical in determining appropriate or inappropriate reac-
tions, at a biochemical level, to a drug, which can be critical 
information for any drug with the potential for undesired, and 
often dangerous or fatal, effects. 
As the more developmentally potent cells of the invention 
can mimic neural stem cells in many regards, relevant infor-
mation pertaining to neural stem cells is presented, followed 
by information pertaining to mesenchymal and retinal stem 
cells. One of skill in the art will readily recognize the methods 
40 ganglia. Huntington's Chorea is associated with the degen-
eration of neurons in the striatum, which leads to involuntary 
jerking movements in the host. Degeneration of a small 
region called the subthalamic nucleus is associated with vio-
lent flinging movements of the extremities in a condition 
45 called ballismus, while degeneration in the putamen and glo-
bus pallidus is associated with a condition of slow writhing 
movements or athetosis. In Parkinson's disease, degeneration 
is seen in another area of the basal ganglia, the substantia 
nigra par compacta. This area normally sends dopaminergic 
50 connections to the dorsal striatum, which are important in 
regulating movement. Therapy for Parkinson's disease has 
centered upon restoring dopaminergic activity to this circuit, 
which can be accomplished by transplantation of more devel-
opmentally potent cells to this region of the brain according to 
55 the instant invention. 
In Alzheimer's disease, another neurodegenerative dis-
ease, there is substantial cellular degeneration of the forebrain 
and cerebral cortex. Further, a localized area of the basal 
ganglia, the nucleus basalis of Meynert, appears to be selec-
60 tively degenerated. This nucleus normally sends cholinergic 
projections to the cerebral cortex, which are thought to par-
ticipate in cognitive functions including memory. 
Mesenchymal Related 
of the invention are not limited to these three types of stem 65 
cells and instead extend to cover all cell types not yet termi-
nally differentiated. 
Although adult stem cells continue to possess some multi-
potency, cell types produced from adult stem cells are limited 
by their tissue-specific character. For example, human NSCs 
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spontaneously differentiate into brain cells under basal media 
conditions, but MeSCs are essentially unable to readily and 
spontaneously differentiate into neural cells without the addi-
tion of certain factors; in the context of the invention, such 
cells are less developmentally potent than cells that could 
differentiate into cells of two or more different lineages. 
These results indicate that each kind of tissue-specific stem 
cell contains specific information that allows it to become a 
special type of cell, i.e., they are partially committed to 
become a particular type of cell in a tissue-specific manner 10 
(i.e., less developmentally potent). To overcome this barrier 
of stem cell lineage and make cells that are more develop-
mentally potent, alterations to the cells and their environment 
are necessary. However, the exact regulation mechanisms of 
tissue-specific stem cell fate decisions remain unclear. This 15 
knowledge base gap poses an important problem, because 
although MeSCs are rather easy to isolate from bone marrow 
and to proliferate in culture, they are essentially unable to 
readily differentiate into NSCs or other non-mesenchymal-
lineage cells. Although the potential therapeutic use of 20 
MeSCs in the central nervous system has been discussed, 
technologies to induce neural lineage in MeSCs had not been 
fully established prior to the instant invention. 
MeSCs of the invention can serve as an alternative to NSCs 
26 
have provided evidence that birds and adult mammals also 
possess a zone of cells at the retinal margin analogous to the 
ciliary marginal zone of cold-blooded vertebrates. These reti-
nal stem cells are reported not only to generate photoreceptor 
and other retinal cells in vitro, but also to differentiate into 
retinal cells following transplantation into the retinal area. 
Although these results indicate the possibility of retinal 
regeneration therapy, an alternative source of stem cells is 
required for clinical applications because the number of reti-
nal stem cells is limited. 
Neural stem cells have been isolated from embryonic and 
adult mammalian brains and have been propagated in vitro in 
a variety of culture systems. Using a serum-free unsupple-
mented media condition, NSCs spontaneously differentiated 
into bIII-tubulin-, glial fibrillary acidic protein (GFAP)-, and 
04-immunopositive cells, markers for neurons, astrocytes, 
and oligodendrocytes, respectively. As described in the 
Examples below, NSCs treated according to methods of the 
invention migrate and differentiate into neurons and glia after 
transplantation into the brains of 24-month-old rats and sig-
nificantly improved the cognitive functions of these animals. 
This result suggested that more developmentally potent cells 
produced according to the invention could provide transplant-
able material to produce a retinal stem cell alternative. 
There is a variety of factors involved in the development of 
retinal tissue that regulate the proliferation and differentiation 
ofretinal cells. Transforming growth factor beta-3 (TGF-b3) 
is thought to regulate cell proliferation during development 
and also influence the commitment or the differentiation, or 
for potential therapeutic use utilizing the methods of the 25 
invention, which exploit the capacity of substituted deoxy-
nucleotide or deoxynucleoside species, such as BrdU, to 
prime the MeSCs, i.e., remove them from their restricted 
mesenchymal differentiation path to the neural stem cell-like 
(or other lineage) differentiation path. MeSCs were success-
fully differentiated into neurons and glia in vitro and in vivo 
using the substituted deoxynucleotide or deoxynucleoside 
pretreatment of the invention. Thus, MeSCs of the invention 
can serve as an alternative to NSCs for potential therapeutic 
use in neuroreplacement utilizing the methods of the inven-
tion. 
30 both, of neural progenitor cells to retinal fates. Treatment of 
embryonic day-18 rat retinal cultures with TGF beta-like 
protein, activinA, causes the progenitor cells in these cultures 
to exit the cell cycle and differentiate into rod photoreceptors, 
indicating that the TGF-family is an important regulator of 
These cells are important in the neuroreplacement therapy 
field because their production permits autologous transplan-
tation. Stem cells can be isolated from the patient, expanded 
in vitro, genetically modified if desired or necessary and 
transplanted back to the same patient. Since neural stem cells 
can be differentiated into most peripheral tissue cells, the 
invention is not only useful to neuroreplacement but to other 
kinds of tissue regeneration or replacement as well. In addi-
tion, since the cells originate from the patient, there are no 
ethical barriers or immunorejection issues with which to con-
tend. 
Retinal Related 
35 photoreceptor differentiation in the developing retina. Treat-
ment of the more developmentally potent cells prepared 
according to the invention with an effective amount of growth 
factor selected from the group consisting ofTGF-b3, IGF-1 
and CNTF, for an effective period, can induce their adoption 
40 of a retinal differentiation path. That is, more developmen-
tally potent cells of the invention, regardless their origin, can 
be made to adopt a retinal differentiation path. Cells not 
treated according to the methods of the invention do not so 
differentiate with simple exposure to these growth factors. 
45 Using the methods of the invention, less developmentally 
potent cells can be transformed into more developmentally 
potent cells and subsequently used as alternatives to retinal 
stem cells to repair ocular tissue damage or promote tissue 
regeneration. 
As described above, "retinal differentiation," as used 
herein, refers to the various cell types found in eye tissue, inter 
alia, chorid, Buchs and retinal pigment epithelium cells, rod 
and cone photoreceptor cells, horizontal cells, bipolar neu-
rons, amacrine, ganglion and optic nerve cells. These non-
55 limiting, exemplary cell types found in eye tissue are collec-
tively referred to as retinal cells. 
Retinal degenerative diseases, including macular degen- 50 
eration, are major causes of blindness. Despite investigations 
into gene therapy, growth/survival factor injections and vita-
min treatments, no effective vision-restoring treatments are 
currently available. Visual impairment caused by the degen-
eration of photoreceptors or neural cells has been considered 
incurable because of a long-held "truism" that neurons do not 
regenerate during adulthood. However, this statement has 
been challenged and there is new evidence that these cells do 
indeed have the potential to be renewed after maturation, thus 
opening a door for the development of novel therapies to treat 
visual impairment by retinal regeneration using stem cell 
transplantation. 
The inventive methods use substituted deoxynucleotide or 
deoxynucleoside compounds to change the cell fate decisions 
ofless developmentally potent cells to more developmentally 
60 potent cells. In the case of retinal transplants, these more 
developmentally potent cells are treated with an effective 
amount of growth factor selected from the group consisting of 
TGF-b3, IGF-1 and CNTF, for an effective period to encour-The capacity for retinal regeneration in cold-blooded ver-
tebrates has long been recognized. Fish and amphibians con-
tinue to make new retinal neurons through a population of 65 
retinal stem cells residing at the peripheral margin of the 
retina, the so-called "ciliary marginal zone." Recent studies 
age their commitment change to the retinal cell lineage. 
There are a variety of neurological and corporal deficits 
that can be addressed using the more developmentally potent 
cells of the invention. 
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"Neurological Deficits" Amenable to Treatment 
Because the invention relates in part to the discovery that 
multipotent precursor cells can be stimulated to divide and 
migrate through the brain, such MSCs can be used to treat 
neurological deficits caused by a wide variety of diseases, 
disorders, and injuries. These insults include, but are not 
limited to, the following. 
Degenerative Diseases 
28 
(wet or dry), post-surgical healing, tumor, heritable retinal 
dystrophies, optic nerve atrophy, and other retinal degenera-
tive diseases. Cells targeted for repair utilizing cells and 
methods of the invention include, for example, choroids, 
Buchs, retinal pigment epithelial (RPE), rods, cones, horizon-
tal cells, bipolar neurons, amacrine, ganglion, and optic 
nerve. 
Injuries and Diseases of the Spinal Cord 
Injuries to or diseases affecting the spinal cord can also be 
treated according to the methods of the invention. Such inju-
ries or diseases include post-polio syndrome, amyotrophic 
lateral sclerosis, nonspecified spinal degeneration, traumatic 
injury (such as those caused by automobile or sporting acci-
dents), including any injury that crushes, partially severs, 
completely severs, or otherwise adversely affects the function 
of cells in the spinal cord), injuries caused by surgery to the 
spinal cord (e.g., to remove a tumor), anterior horn cell dis-
ease, and paralytic diseases. 
Demyelinating or Autoimmune Disorders 
Degenerative diseases that can be treated according to the 10 
methods of the invention include Alzheimer's disease (AD), 
Parkinson's disease (PD), Huntington's disease (HD), Pick's 
disease, progressive supranuclear palsy (PSP), striatonigral 
degeneration, cortico-basal degeneration, childhood disinte-
grative disorder, olivopontocerebellar atrophy (OPCA; 15 
including a heritable form), Leigh's disease, infantile necro-
tizing encephalomyelopathy, Hunter's disease, muco-
polysaccharidosis, various leukodystrophies (such as 
Krabbe's disease, Pelizaeus-Merzbacher disease, and the 
like), amaurotic (familial) idiocy, Kuf's disease, Spielmayer- 20 
Vogt disease, Tay Sachs disease, Batten disease, Jansky-
Bielschowsky disease, Reye's disease, cerebral ataxia, 
chronic alcoholism, beriberi, Hallervorden-Spatz syndrome, 
and cerebellar degeneration. 
Neurological deficits caused by demyelination or an 
autoimmune response can be treated according to the meth-
ods of the invention. Such deficits can be caused by multiple 
25 sclerosis, or lupus. Traumatic and Neurotoxic Injuries to the Central Nervous 
System 
Traumatic and neurotoxic injuries that can be treated 
according to the methods of the invention include gunshot 
wounds, injuries caused by blunt force, injuries caused by 
penetration injuries (e.g., stab wounds), injuries caused in the 30 
course of a surgical procedure (e.g., to remove a tumor or 
abscess from the CNS or to treat epilepsy), poisoning (e.g., 
with MPTP or carbon monoxide), shaken-baby syndrome, 
adverse reactions to medication (including idiosyncratic 
reactions), drug overdose (e.g., from amphetamines), and 35 
post-traumatic encephalopathy. 
Ischemia 
Infectious or Inflammatory Diseases 
Neurological deficits caused by an infection or inflamma-
tory disease can be treated according to the methods of the 
invention. Infections or inflammatory diseases that can cause 
treatable deficits include Creutzfeldt-Jacob disease and other 
slow virus infectious diseases, AIDS encephalopathy, post-
encephalitic Parkinsonism, viral encephalitis, bacterial men-
ingitis and meningitis caused by other organisms, phlebitis 
and thrombophlebitis of intracranial venious sinuses, syphi-
litic Parkinsonism, and tuberculosis of the CNS. 
In addition to the deficits, diseases and disorders set forth 
explicitly above, those of ordinary skill in the art are well able 
to recognize neurological deficits, regardless of their cause, Any disruption of blood flow or oxygen delivery to the 
nervous system can injure or kill cells, including neurons and 
glial cells, therein. These injuries can be treated according to 
the methods of the present invention and include injuries 
caused by a stroke (including a global stroke (as may result 
from cardiac arrest, arrhythmia, or myocardial infarction) or 
a focal stroke (as may result from a thrombus, embolus, 
hemorrhage, or other arterial blockage)), anoxia, hypoxia, 
partial drowning, myoclonus, severe smoke inhalation, dys-
tonias (including heritable dystonias ), and acquired hydro-
cephalus. 
40 and to apply the methods of the present invention to treat 
patients who have such deficits. In addition to the conditions 
listed above, that are amenable to treatment with the methods 
described herein, neurological deficits can be caused by 
Lesch-Nyhan syndrome, myasthenia gravis, various demen-
Developmental Disorders 
45 tias, numerous parasitic diseases, and epilepsy. Further, alle-
viation of age-related memory loss is an object of the inven-
tion. The methods of the invention can be readily applied to 
alleviate neurological deficits caused by these and other dis-
eases, disorders, or injuries. 
50 
Developmental disorders that can be treated according to 
the methods of the invention include schizophrenia, certain 
forms of severe mental retardation, cerebral palsy (whether 
caused by infection, anoxia, premature birth, blood type 
incompatibility: etc. and whether manifest as blindness, deaf- 55 
ness, retardation, motor skill deficit, etc.), congenital hydro-
cephalus, metabolic disorders affecting the CNS, severe 
autism, Down Syndrome, LHRH/hypothalamic disorder, and 
"Corporal Deficits" Amenable to Treatment 
The invention also relates to the amelioration of corporal 
deficits utilizing multipotent precursor cells stimulated to 
divide, migrate through damaged tissue and differentiate in a 
tissue-specific manner. Cells according to the invention can 
be used to treat corporal deficits caused by a wide variety of 
diseases, disorders, and injuries, the result of which is trauma, 
malfunction, degeneration or loss of muscle such as, for 
example, cardiac muscle due to myocardial infarction. Other 
spina bifida. 
Disorders Affecting Vision 
Disorders affecting vision, particularly those caused by the 
loss or failure of retinal cells, can be treated according to the 
methods and cells of the invention. These disorders include, 
for example, diabetic retinopathy, serious retinal detachment, 
retinal damage associated with glaucoma, traumatic injury to 
the retina, retinal vascular occlusion, macular degeneration 
60 examples include malfunction, degeneration or loss of other 
cells and tissues apart from those discussed in the neurologi-
cal deficit section above such as, for example, internal organs. 
For example, liver function can be adversely affected by, 
among other things, disease (e.g., cirrhosis or hepatitis), 
65 trauma or age. Other exemplary internal organs amenable to 
treatment utilizing the embodiments of the invention include 
heart, pancreas, kidney, stomach, and lung. Corporal deficits 
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also comprise malfunction, degeneration or loss of skeletal 
assets such as, for example, vertebrae. 
Reelin andAmyloid Precursor Protein (APP) 
Reelin 
30 
Neurogenesis in animals lacking the more developmen-
tally potent cells of the present invention is dependent on 
endogenous NSCs. Islands of NSCs have been detected in 
embryonic and adult mammalian brains, and due to their 
pluripotent differentiation potential, they can differentiate 
into astrocytes, neurons, or oligodendrocytes. Recent studies 
have observed NSCs in the anterior subventricular zone 
(SVZ) and dentate gyrus of the adult brain, indicating that 
neurogenesis may occur throughout life. Although pluripo-
tency of endogenous, adult NSCs is regionally and tempo-
rally restricted, these cells retain their ability to migrate and 
differentiate in response to environmental cues. As described 
now know that reelin is expressed in several neuronal popu-
lations in the adult brain (Pesold et al., 1998, Proc. Natl. A cad. 
Sci. USA 95: 3221-6; Pesold et al., 1999, Proc. Natl. Acad. 
Sci. USA 96: 3217-22). This protein is thought to be operative 
in other important functions, for example, the reelin haploin-
sufficient heterozygous reeler mouse exhibits decreased den-
dritic spine expression density in pyramidal neurons of the 
cortex and hippocampus and reelin and alpha-3-integrin (a3-
integrin) receptor subunit immunoreactivities colocalize to 
10 dendritic spine postsynaptic densitie, which supports a role 
for reelin in adult brain neuroplasticity (spine formation and 
synaptogenesis) that requires protein synthesis. Such studies 
draw a reasonable connection to the observation that 
in Example 1 below, human NSCs that were injected into the 
lateral ventricle of 24-month-old rats showed a symmetrical 
migration in the host brain followed by differentiation into 
neurons and glial cells. This result indicates that the aged 
brain maintains regulatory mechanisms to guide the migra-
tion of NSCs, and exogenous more developmentally potent 
cells of the invention, that may be indispensable for proper 
adult brain neuroplasticity. 
15 depressed reelin levels have been observed in victims of 
schizophrenia and autism. Deficiencies in neuroplasticity and 
stem cell migration could be seen to reduce or prevent the 
endogenous stem cell population or exogenous, more devel-
opmentally potent cells of the invention from migrating to the 
20 regions of need in the brain. 
Our studies indicate that reelin plays an important role in 
regulation ofNSC biology. The addition of recombinant ree-
lin to NSCs in culture increased mobility of cells in the cluster 
of cells that typified their growth. When NSCs were trans-
25 planted in the brain of reeler homozygous mice, mice that do 
not express reelin, migration was nearly halted; in contrast, 
NSCs migrated and displayed a beautifully symmetrical dis-
tribution in wild-type mice brain after transplantation. We 
Recent studies (Corbin et al., 2001, Nat Neurosci 4 Supp. 1: 
1177-827; Marin et al., 2001, Nat Rev Neurosci 2: 780-901) 
have revealed two distinct neuronal migration patterns: radial 
and tangential. Each pattern consists of two different neu-
ronal populations that participate in corticogenesis. One neu- 30 
ronal population proliferates from the embryonic SVZ and 
migrates along the radial glia to reach the subcortical plate, 
detaches from radial glia scaffolding, and then penetrates the 
subcortical plate guided by reelin gradient secreted by 
gamma amino butyric acid (GABA)-ergic Cajal-Retzius cells 35 
(D'Arcangelo et al., 1995, Nature 374: 719-23). A second 
neuronal population consists of tangentially migrating neu-
roblasts that proliferate in the SVZ in the mantle of ganglionic 
telencephalic eminences and give rise to GABA-producing 
inter-neurons (Anderson et al., 2001, Development 128: 353- 40 
63). In the adult brain, host glial cells respond to the trans-
plantation of NSCs (Leavitt et al., 1999, Exp. Neural 157: 
43-57) and lesions (Yang et al., 1997, Exp Neurol 146: 199-
205) by becoming transient radial gliatype cells, which may 
serve to guide migration in adult neurogenesis. In contrast, 45 
subsets of cells expressed in the ventral piriform cortex and 
olfactory bulb migrate long distances without a radial glia 
connection (Durbec et al., 2001, Mal Cell Neurosci 17: 561-
76), suggesting that specific regulatory mechanisms guide 
NSC migration in the adult brain and that some of these 50 
mechanisms are very likely analogous to those operative dur-
ing development. 
Reelin is a large extracellular matrix (ECM) protein of 
approximately 400 kDa, which binds to the a3 subunit of 
integrin receptors expressed on neuronal cell surfaces, very 55 
low density lipoprotein receptor (VLDLR) and Apolipopro-
tein E receptor 2 ( ApoER2 ), triggering the adaptor function of 
the disabled-I (Dab-1) cytosolic protein. The clustering of 
integrin receptor subunits following reelin binding activates a 
tyrosine kinase (focal adhesion kinase) to phosphorylate 60 
Dab-1. This phosphorylated Dab-1 binds and transports 
soluble tyrosine kinases and transcription factors to func-
tional cellular compartments. In the null reeler mouse, 
migrating neurons fail to penetrate the subcortical plate, 
likely due to a deficiency of serine protease activity associ- 65 
ated with reelin. While much attention has been focused on 
role of reelin in neuronal migration during corticogenesis, we 
found that only cells expressing reelin migrated into the cor-
tex of reeler homozygous mice. These results suggest that 
reelin is an indispensable factor for the migration ofNSCs or 
more developmentally potent cells of the invention, and the 
epigenetically downregulated reelin expression in schizo-
phrenia and autism patients causes a deficit in migration and 
neuroplasticity potentially associated with those phenotypes. 
Reelin is preferentially expressed in GABAergic neurons in 
the adult cortex, so some of the loss ofGABAergic interneu-
rons in the neocortex of schizophrenia may be explained by 
this mechanism as well. 
Mammals with suppressed reelin expression may not expe-
rience proper migration of endogenous or exogenous multi-
potent cells in the brain. Thus, reelin levels could be raised 
through genetic engineering approaches, i.e., the introduction 
of cells expressing reelin or appropriate vectors for endog-
enous cells transfection, to stimulate migration at the possible 
expense of some additional glial differentiation. The reelin 
protein can be administered to a mammal in need. For 
example, reelin can be introduced at the site of a stroke to 
encourage the migration of multipotent cells into the area of 
damage to start repair. Drugs that increase reelin expression 
or reelin levels in general may also be administered in an 
amount sufficient to raise reelin levels enough to enable 
proper migration. Similarly, the biological activity of the 
reelin present in an animal depends also on reelin receptor. 
Altering reelin receptor abundance or affinity for reelin can 
enhance the activity or suppress the activity of any reelin 
preset in the animal. The present invention contemplates the 
use genetic techniques to supplement or alter the natural 
supply of reelin receptors through genetic techniques well 
known in the art to influence cell migration. Similarly, the 
invention provides a method of altering the differentiation of 
endogenous or exogenous multipotent stem cells in a mam-
mal by altering the amount or binding affinity of APP receptor 
in the mammal. Such methods may help those afflicted with 
schizophrenia and autism. 
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Thus the alteration of reelin levels may be used to influence 
the migration of endogenous NSCs as well as exogenous 
multipotent cells such as the more developmentally potent 
cells of the invention. 
APP 
32 
N-terminal of APP prevents the differentiation of NSCs. 
These findings indicate that APP signaling is one of the regu-
latory systems involved in the differentiation of NSCs. We 
also found that NSCs transplanted into the APP knockout 
mouse brain could not migrate properly and failed to repair 
brain lesions, whereas NSCs transplanted into wild-type 
mouse successfully migrated into the proper position and 
differentiated in a tissue-appropriate manner. This result is 
not only the first finding of a phenotypical change in APP-
10 knockout mice, but also indicates a physiological role for 
APP in the regeneration of adult brain cells. Furthermore, we 
found that the addition of a higher concentration of sAPP or 
the over-expression of APP by transgenes to NSC cultures 
caused glial rather than neural differentiation of these cells. 
While many factors are released following apoptotic cell 
death, several studies point to an important correlation 
between apoptosis and the amyloid precursor protein (APP). 
Damaged neurons and neurons committed to apoptosis dem-
onstrate signals strongly immunopositive for APP. Moreover, 
amyloidgenic fragments produced from APP are released into 
the extracellular space from neuronal cells under serum-de-
prived conditions. The expression of APP is also reported to 
increase during retinoic acid-induced neuronal differentia-
tion. The mRNA expression of beta-amyloid (b-amyloid) 
precursor-like proteins (APLP-1 and APLP-2) is also up-
regulated during retinoic acid induced differentiation of 
human SH-SY5Y neuroblastoma cells. The increase in APP 
expression levels during neuronal differentiation in various 20 
cell culture systems suggests an important cellular function 
for APP during the differentiation process. From these obser-
vations, it appears that under serum-free differentiation con-
ditions, APP fragments released from apoptotic cells serve as 
regulation and differentiation factors for neighboring stem 25 
cells. 
15 These findings indicate that the pathological alteration of 
APP metabolism inAD induces glial differentiation of neural 
stem cells and could leads to the exhaustion of the stem cell 
population, which may be important for ongoing neurogen-
esis in the adult brain. 
To prevent or remedy any exhaustion of endogenous stem 
cell populations in the brain, more developmentally potent 
cells of the invention can be administered according to the 
methods of the invention to the mammal with increased APP 
production. Such action may act to overwhelm the excess 
APP such that increased glial differentiation of the multipo-
tent cells is nevertheless accompanies with significant proper 
APP is also known to be up-regulated during development 
and after brain damage, both of which are events that involve 
migration and differentiation ofNSCs. Secreted APP (sAPP) 
has also been reported to produce protein kinase C and syn-
aptogenesis in cultured neurons, in addition to significantly 
enhancing proliferation and growth of neural stem cells. 
Moreover, it has been shown that sAPP is able to activate 
MAPK (ERK) in PC12 cells via the Ras pathway. Since 
MAPK activation can induce proliferation or differentiation, 
sAPP may activate this pathway in proximal stem cells and 
induce cell differentiation. These facts, together with several 
of the examples below, indicate that one ofAPP's physiologi-
cal functions may be the regulation of stem cell biology in the 
brain to allow forthe successful formation and replacement of 
proper structures and neuronal circuits. sAPP released from 
damaged or dying cells may preferentially induce glial dif-
ferentiation of a population of NSCs and this may act to 
reconstruct neuronal circuits by the guidance of NSCs to 
areas of damage. The stem cell-derived glial cells can then 
produce factors that can support surrounding damaged cells 
and promote neuronal migration and differentiation of other 
NSCs in this area. Our in vitro observations that the initial 
apoptotic cell death-induced glial differentiation was fol-
lowed by neuronal differentiation (Brannen et al., 2000, Neu-
roreport 11: 1123-8) supports this view. Thus, under normal 
physiologic conditions, APP can be necessary to recover from 
brain damage. In the case of familial AD, the increased levels 
of APP fragments produced in the brains of these patients may 
modify the biological equilibrium ofNSCs in such a way that 
a pathological shift towards premature differentiation of 
NSCs will occur, thereby depleting or exhausting the NSC 
population. Since the effective natural replacement of degen-
erating neurons in the adult brain during aging or disease 
process may be important in maintaining normal brain func-
tion, the NSC population exhaustion would hinder such 
replacement. 
In preliminary studies, we found evidence that APP frag-
ments are secreted from apoptotic HNSCs and induce differ-
entiation of other NSCs in vitro. We also observed that exog-
enously added secreted-type APP (sAPP) induces the 
differentiation of NSCs, while antibody-recognizing the 
migration and differentiation to replace degenerating neu-
rons. Alternatively, anti-APP antibody can be used to lower 
excessive APP levels. Anti-APP antibody can be adminis-
30 tered to the mammal with overabundant APP such that the 
APP levels are reduced in an amount sufficient to prevent glial 
differentiation of the endogenous or exogenous multi potent 
stem cell population. Genetic engineering methods can be 
used to introduce a vector that expresses anti-APP antibody in 
35 the mannnal with elevated APP levels. Such a method pre-
vents the need for repeated administration of the antibody 
protein itself. Furthermore, drugs that lower APP expression 
or APP levels in general can be administered. 
Mannnals with suppressed APP expression may not expe-
40 rience proper migration of endogenous or exogenous multi-
potent cells in the brain. Thus, APP levels could be raised 
through genetic engineering approaches, the introduction of 
cells expressing APP or appropriate vectors for endogenous 
cells transfection, in some instances expressing at relatively 
45 low levels, to stimulate migration at the possible expense of 
some additional glial differentiation. The APP protein can be 
administered to a mannnal in need. For example, APP can be 
introduced at the site of a stroke to encourage the migration of 
multipotent cells into the area of damage to start repair. Glial 
50 differentiation is an important part of the healing process in 
the brain. Drugs that increase APP expression or APP levels in 
general may also be administered in an amount sufficient to 
raise APP levels enough to enable proper migration. 
As with reelin, the biological activity of the APP present in 
55 an animal depends also on APP receptor. Altering APP recep-
tor abundance or affinity for APP can enhance the activity or 
suppress the activity of any APP preset in the animal. The 
present invention contemplates the use genetic techniques to 
supplement or alter the natural supply of APP receptors 
60 through genetic techniques well known in the art to influence 
cell migration and/or proliferation. 
Thus the alteration of APP levels may be used to influence 
the migration and differentiation of endogenous NSCs as well 
as exogenous multipotent cells such as the more developmen-
65 tally potent cells of the invention. 
An advantage of the cells of the invention is that they can be 
genetically engineered according to routine procedures 
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known in the art (See, e.g., SAMBROOK, ET AL., 
MOLECULAR CLONING: A LABORATORY MANUAL. 
3Rn EDITION, COLD SPRING HARBOR LABORATORY, 
2001 ). As mentioned above, in preferred embodiments, con-
structs encoding reelin can be provided to the cells. In other 
preferred embodiments, constructs that inhibit expression of 
APP (such as ribozymes, antisense molecules, or other means 
of inhibiting APP expression) can be provided. In further 
embodiments, drug resistance genes and markers, or detect-
able markers such as GFP can be provided. Preferably, the 
marker and other genes are operably and genetically linked to 
gene expression regulatory elements (including but not lim-
ited to promoters and enhancers) that are operable in the 
terminally differentiated cell derived from MSCs of the 
invention or in the undifferentiated MSCs of the invention or 
both. 
The following examples are presented in order to more 
fully illustrate the preferred embodiments of the invention. 
They should in no way be construed, however, as limiting the 
scope of the invention, as defined by the appended claims. 
EXAMPLES 
Example 1 
Improvement of Cognitive Function in Aged Rat by the 
Transplantation ofNSCs of the Invention 
34 
These behavioral results indicate the beneficial effects of 
the transplantation ofBrdU-treated human NSCs into the host 
brain. After the second water maze task, postmortem brains 
were further analyzed by immunohistochemistry for human 
bIII-tubulin and human GFAP, markers for neurons and astro-
cytes respectively. There was no sign of ventricular distortion, 
no evidence of tumor formation, and no strong host anti-graft 
immunoreactivity was observed as revealed by weak host 
astrocyte staining. Intensely and extensively stained with 
10 bIII-tubulin, neurons with BrdU-positive nuclei were found 
in bilateral singular and parietal cortexes (FIGS. 4a-c) and 
hippocampus (FIGS. 4d,e). The bIII-tubulin-positive neurons 
found in the cerebral cortex were typified by a dendrite point-
ing to the edge of the cortex. In the hippocampus, donor-
15 derived neurons exhibited multiple morphologies, varying in 
cellular size and shape, and one or more processes and 
branching. 
Generally, GFAP-positive astrocytes were localized near 
the area where neuronal cells were found. On further analysis 
20 (overlapping images of their distributions), donor-derived 
astrocytes were found to co-localize with neuronal fibers in 
the cortex (FIG. 4/). These astrocytes were larger than the host 
glia, with cell bodies 8-10 microns in diameter and thick 
processes. Some of these astrocytes had a unilateral morphol-
25 ogy (asymmetric), and the immunostaining formed a thin ring 
around the nucleus, while the majority of the processes were 
formed on the other side. Most cells appeared a symmetrical 
with processes forming from all sides. The absence of this 
Human NSCs do not require any exogenous factors for 
differentiation and survived more than three weeks in basal 30 
type of cell in normal animal without the transplantation of 
treated human NSCs was confirmed using immunohis-
tochemistry for rat astrocytes. host astrocytes had small cell media without the addition of any factor to support their 
survival (Qu et al., 2001, Neuroreport 12: 1127-32). Thus, it 
appears that human NSCs produce factors to differentiate and 
support themselves, which suggested that these cells could be 
transplanted into aged animals after treatment according to 35 
the methods of the invention. 
bodies with multiple delicate processes, and were distributed 
throughout the brain mainly in white matter and around the 
edges of the brain. 
These results demonstrated that transplanted cells of the 
invention migrated in rat brain and differentiated into appro-
priate cell types. The concomitant improvement in cognitive 
function indicated that transplanted more developmentally 
potent cells of the invention were functionally integrated into 
Human NSCs, expanded without differentiation under the 
influence of mitogenic factors in supplemented serum-free 
media and pre-treated by the incorporation of bromodeox-
yuridine (BrdU) into the nuclear DNA, were injected into the 
lateral ventricle of mature (6-month-old) and aged (24-
month-old) rats. Human NSCs prepared according to the 
methods of the invention survived 30 days after xenotrans-
plantation into aged rat brain, while retaining both multipo-
tency and migratory capacity, and also improved cognitive 
function in 24-month-old rats. Cognitive function of the ani-
mals was assessed by the Morris water maze both before and 
four weeks after the transplantation of human NSCs of the 
invention. Before human NSC transplantation, some aged 
animals (aged memory unimpaired animals) cognitively 
functioned in the range of mature animals, while others (aged 
memory impaired animals) functioned entirely out of the 
cognitive range of the mature animals. After transplantation 
of the BrdU-treated human NSCs, most aged animals had 
cognitive function in the range of the mature animals. Strik-
ingly, one of the aged memory-impaired animals showed 
dramatic improvement in its behavior, functioning even better 
than the mature animals (FIG. 2a ). Statistical analysis showed 
that cognitive function was significantly improved in both 
mature and aged memory-impaired animals but not in aged 
memory-unimpaired animals after BrdU-treated human NSC 
transplantation (FIG. 2b ), which may be due to the physical 
limitations of the aged animals. The performance of three of 
the aged animals deteriorated in the water maze after trans-
plantation of treated human NSCs. It is possible that the 
physical strength of these animals deteriorated during the 
experimental period. 
40 the recipient brains. 
The following methods were used in this and several of the 
following examples: 
The Morris Water Maze: The Morris water maze consists 
of a large circular tank (diameter, 183 cm; wall height, 58 cm), 
45 filled with water (27° C.) and opacified by the addition of 
powdered milk (0.9 kg). Beneath the water surface (1 cm) 
near the center of one of the four quadrants of the maze a clear 
escape platform (height, 34.5 cm) is positioned. The rats 
receive three training trials per day for seven consecutive 
50 days, using a 60 sec inter-trial interval. A training trial con-
sists of placing the animal in the water for 90 seconds or until 
the swimming rat successfully locates the platform. If the rat 
fails to find the platform within the 90 seconds, the animal is 
gently guided to the platform. For spatial learning assess-
55 ment, the platform's location remains constant in one quad-
rant of the maze, but the starting position for each trial is 
varied. Every sixth trial is a probe trial, during which the 
platform is retracted to the bottom of the pool for 30 sec and 
then raised and made available for escape. The training trials 
60 assess the acquisition and day-to-day retention of the spatial 
task while the probe tests are used to assess search strategy. At 
the completion of a spatial learning assessment, one session 
with six trials of cue training is performed Rats are trained to 
escape to a visible black platform that is raised 2 cm above the 
65 surface of the water. The location of the platform is varied 
from trial to trial to assess sensorimotor and motivational 
functioning independent of spatial learning ability. Each rat is 
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given 30 seconds to reach the platform and is allowed to 
remain there briefly before the 30 second inter-trial interval. 
Accuracy of performance is assessed using a learning index 
score computed from the probe trials. The learning index is a 
derived measure from average proximity (cumulative search 
error divided by the length of the probe trial) on the second, 
third, and fourth interpolated probe trials. Scores from these 
trials are weighted and summed to provide an overall measure 
of spatial learning ability. Lower scores on the index indicate 
a more accurate search near the target location; higher scores 10 
indicate a more random search and poor learning. 
Cell migration and differentiation: In order to investigate 
differentiation and/ or migration of cells of the invention in the 
brain, more developmentally potent cells were transplanted 
into rodent brain. The animals were anesthetized with 50 15 
mg/kg pentobarbital (i.p.) and mounted in a stereotaxic appa-
ratus (David Kopi). Approximately lxl04 to lxl05 cells in 5 
36 
tions using a cryomicrotome. The sections were washed 
briefly in PBS and pretreated with IM HCl for 30 minutes at 
room temperature and neutralized with sodium borate ( 0.1 M, 
pH 8.0) for 30 minutes in order to increase the accessibility of 
an anti-BrdU antibody to BrdU incorporated :in the cell 
nuclei. After rinsing with PBS, sections were transferred to a 
solution containing 0.25% Triton X-100 in PBS (PBST) for 
30 minutes. The sections were then blocked by incubation in 
PBST containing 3% donkey normal serum for 1 hour, fol-
lowed by incubating the sections overnight at 48° C. with 
sheep anti-BrdU (1: 1000; Jackson IR Laboratories, Inc. West 
Grove, Pa.) or mouse anti-BrdU (1:200; DSHB, Iowa City, 
Iowa) diluted in PBST. After rinsing the sections in PBS, 
donkey anti-mouse or donkey anti-sheep conjugated to 
rhodamine IgG (Jackson IR Laboratories, Inc.) was added at 
a 1 :200 dilution in PBST and the sections further incubated 
for 2 hours at room temperature in the dark. 
The transplanted cells of the invention, with BrdU immu-
nopositive nuclei, were stained for human bIII-tubulin and 
human glial filament protein (GFAP). The sections were then 
washed with PBS and incubated with mouse IgG2b mono-
clonal anti-human bIII-tubulin, clone SDL3D10 (1:500, 
Sigma), goat antihuman GFAP, N-terminal human affinity 
purified (1:200, Research Diagnostics Inc., Flander, N.J.) or 
mouse IgGl monoclonal anti-GFAP, clone G-A-5 (1:500, 
Sigma), respectively, overnight at 48° C. in the dark. After 
brief washing with PBS to remove excess primary antibody, 
the location of primary antibody binding was then determined 
using FITC-conjugated (Jackson IR Laboratories, Inc.) sec-
ondary antibody (donkey anti-mouse (1:200) or donkey anti-
goat IgG (H+L; 1:200), respectively) by incubating the sec-
tions for 2 hours at room temperature in the dark. 
The sections were then washed with PBS thoroughly 
before mounting to glass slides. The mounted sections were 
µl phosphate-buffered saline were injected into the ventricle 
using a microsyringe attached to the stereotaxic apparatus. 
After removing the hair from the surgical site using electric 20 
razor, an iodine swab was be applied to the area and a 0.5 cm 
surgical incision was made caudal to rostral in the skin at the 
surface of the cranium. The ventricle was stereotaxically 
localized using the following exemplary coordinates: AP=-
0.58 mm from bregma, ML=+ 1 mm, and 2.4 mm below dura 25 
(for mouse): AP=-1.4 mm from bregma, ML=+3.3 mm, and 
4.5 mm below dura (for rat). A 0.4-mm hole was made in the 
cranium by careful drilling. The cells of the invention were 
injected into the ventricle using a microsyringe. The injection 
was delivered over a period of five minutes and the needle was 30 
left in place for an additional two minutes following the 
injection. After the injection, the surgically incised skin was 
closed by Michel suture clip (2.5xl .75 mm). Ten days post-
surgery, proper healing of the incision site was observed, and 
the Michel sutures were removed. 35 covered with Vectashield using 4',6-diamidine-2-phenylin-
dole. 2HC1 (DAPI, Vector Laboratories, Inc., Burlingame, 
Calif.) for fluorescent microscopic observation. Microscopic 
images were taken by using an Axiocam digital camera 
mounted on the Axioscope 2 with Axiovision software 
Cell migration and differentiation: In order to investigate 
differentiation and/ or migration of cells of the invention in the 
brain, more developmentally potent cells were transplanted 
into rodent brain. The animals were anesthetized with 50 
mg/kg pentobarbital (i.p.) and mounted in a stereotaxic appa-
ratus (David Kopf). Approximately lxl04 to lxl05 cells in 5 
µl phosphate-buffered saline were injected into the ventricle 
using a microsyringe attached to the stereotaxic apparatus. 
After removing the hair from the surgical site using electric 
razor, an iodine swab was be applied to the area and a 0.5 cm 
surgical incision was made caudal to rostral in the skin at the 
surface of the cranium. The ventricle was stereotaxically 
localized using the following exemplary coordinates: AP=-
0.58 mm from bregma, ML=+ 1 mm, and 2.4 mm below dura 
(for mouse): AP=-1.4 mm from bregma, ML=+3.3 mm, and 
4.5 mm below dura (for rat). A 0.4-mm hole was made in the 
cranium by careful drilling. The cells of the invention were 
injected into the ventricle using a microsyringe. The injection 
was delivered over a period of five minutes and the needle was 
left in place for an additional two minutes following the 
injection. After the injection, the surgically incised skin was 
closed by Michel suture clip (2.5xl .75 mm). Ten days post-
surgery, proper healing of the incision site was observed, and 
the Michel sutures were removed. 
40 (Zeiss). 
The transplanted MNSCs, with BrdU immunopositive 
nuclei, were stained for human bIII-tubulin and human GFAP. 
Double immunolabeling with bIII-tubulin and BrdU in three 
different planes from the same microscopic view clearly 
45 showed the co-localization of these two signals in the same 
cells (FIG. 5). According to the manufacturer's description, 
the anti-bIII-tubulin antibody may also recognize the host 
(rat) bIII-tubulin. Despite this, the specific co-localization of 
the bIII-tubulin and BrdU at different planes indicate that the 
50 majority of bIII-tubulin immunopositive cells were indeed 
transplanted cells of the invention. This may be because bIII-
tubulin is mainly expressed in immature neurons, the major-
ity of which are transplanted cells as disclosed herein. The 
presence of these cell specific antigens indicates that the 
55 transplanted cells of the invention successfully differentiated 
into neurons and astrocytes, respectively. 
NSC culture: NSCs were purchased (Bio Whittaker, Walk-
The existence and location of the cells of the invention after 60 
ersville, Md.), and alternatively isolated from human tissue, 
and cultured in a nonsupplemented, serum-free basal medium 
comprising HAMS-F12 (Gibco, BRL, Burlington, ON); anti-
biotic-antimycotic mixture (1:100, Gibco ); B27 (1:50, administration in rat brain was analyzed as follows. At 30 
days post-transplantation, the rats were sacrificed by an over-
dose of sodium pentobarbital (70 mg/kg, i.p.) and perfused 
with phosphate buffered saline (PBS) followed by 4% 
parafonnaldehyde. Brains were removed and incubated over-
night in 4% paraformaldehyde fixative containing 20% 
sucrose. The brains were sliced into 20 micron coronal sec-
Gibco ); human recombinant FGF-2 and EGF (20 ng/ml each, 
Rand D Systems, Minneapolis, Minn.) and heparin ( 5 ug/ml, 
Sigma, St. Louis, Mo.). The cells were incubated at about 37° 
65 C. in a 5% C02 humidified incubation chamber (Fisher, Pitts-
burgh, Pa.). To facilitate optimal growth conditions, clusters 
of one or more NSCs were sectioned into quarters every 2 
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weeks and fed by replacing 50% of the medium every 4-5 
days. To inhibit differentiation, the cells can be propagated on 
uncoated flask or a flask that has been treated to repel the cells. 
To induce differentiation, these cells can be replated in the 
culture dishes (about lxl05 per dish) in the serum-free basal 5 
medium Eagle (BME), which comprises Earle's salt and 
L-glutamine, and cultured for about 5 days in the absence of 
FGF-2 and EGF and without the addition of other extrinsic 
differentiation factors. NSCs cultured in this serum-free 
medium can spontaneously undergo differentiation into neu- 10 
ronal cell types. 
Example 2 
38 
cell populations, including neural precursors that formed a 
cluster of two or more cells in the middle, and coronary 
migrating immature and/or mature neurons and astrocytes 
(FIG. 7). MeSCs treated with BrdU were then transferred 
onto a tissue culture 0.4 µm membrane insert (Falcon) and 
placed on top of the differentiated NSCs in basal media con-
ditions. 
Immunocytochemical examination seven days post-cocul-
ture revealed that BrdU-treated MeSCs differentiated into 
bIII-tubulin immunopositive small bipolar and unipolar cells 
(approximately 40% of total cells), and GFAP-immunoposi-
tive large flattened multipolar cells (approximately 60% of 
total cells) (FIG. 8). Although the process of bIII-tubulin 
immunopositive cells derived from MeSCs was shorter than 
Neural Differentiation ofMeSCs In Vitro 
15 those found in differentiated NSCs, the general morphology 
of the cells in both NSCs and MeSCs-differentiated cultures 
Neural stem cells have been isolated from embryonic and 
adult mammalian and human (Doetsch et al., 1999, Cell 97: 
703-16; Johansson et al., 1999, Cell 96: 25-34) central ner-
vous system (CNS) and propagated in vitro in a variety of 20 
culture systems (Svendsen et al., 1999, Brain Pathol. 9: 499-
513). The inability to grow neural progenitors in culture in the 
absence of complex and undefined biological fluids (for 
example, serum) has long been a major obstacle in under-
standing the physiology of these cells. Long-term culture 25 
systems to proliferate MeSCs and NSCs were established 
(Brannon et al., 2000, Neuroreport 11: 1123-8). The ability of 
multipotent human NSCs to expand in vitro produces well-
characterized material for biological research. As grown in 
ling term culture, NSCs are differentiated into bIII-tubulin- 30 
and glial fibrillary acidic protein (GAFP)-immunopositive 
cells (Brannon et al., 2000, Neuroreport 11: 1123-8). After 
three years of in vitro expansion, such human NSCs remain 
capable of producing neurons and glia on differentiation 
(FIG. 6(I)) under non-serum basal media conditions, indicat- 35 
ing the multipotency of these cells, thus demonstrating that 
this culture system is optimal to maintain NSCs and to inves-
tigate their biology. NSCs were also differentiated in co-
culture with an oxidatively damaged human neuronal cell line 
(Sy5). The overnight culture of Sy5 cells were grown in the 40 
media described elsewhere herein, treated with 0.0, 0.01, 0.03 
or 0.1 µM H20 2 in NSC media for 15 minutes, thoroughly 
washed with DMEM-F12 media, then co-cultured with 
NSCs. The results (FIG. 6(II)) indicate that the can be differ-
entiated into neurons and astrocytes by responding to dam- 45 
aged neuronal cells even after lengthy in vitro expansion. 
The fate of stem cells is greatly influenced by contextual 
cues. Stem cells can respond and differentiate into specific 
cell types according to the environmental cues to which they 
are exposed. Further, when cells that are incapable of differ- 50 
entiating in response to environmental cues (such as MeSCs 
which do not respond to neural environmental cues) are 
treated with substituted deoxynucleotide or deoxynucleo-
sides according to the methods of the invention, they are 
rendered capable of so differentiating. They become more 55 
developmentally potent in character. Herein is demonstrated 
that neural tissue produces environmental factor(s) that can 
initiate neural lineage in MeSCs pretreated with BrdU. 
MeSCs were co-cultured with differentiated NSCs after 
BrdU treatment (10 µM BrdU for 5 days before co-culture) of 60 
the MeSCs. MeSCs did not differentiate into neurons or glia 
(bIII-tubulin and GFAP negative) after use of serum or basal 
differentiation conditions (data not shown). NSCs were dif-
ferentiated in 12-wells tissue culture plates under the basal 
media condition; i.e., serum-free basal medium containing 65 
Earle's salt and L-glutamine (Invitrogen) for five days prior to 
co-culture. NSCs spontaneously differentiated into mixed 
were similar (FIG. 8). This result indicated that BrdU pre-
treated MeSCs are capable of becoming neurons and astro-
cytes when co-cultured with differentiated NSCs. On the 
other hand, MeSCs without BrdU treatment did not express 
either bIII-tubulin or GFAP immunoreactivity and remained 
in a fibroblast-like morphological state even after co-culture, 
demonstrating clear evidence that substituted deoxynucle-
otide or deoxynucleoside treatment is necessary to initiate 
neural lineage change in MeSCs. 
Since no exogenous differentiation factors such as, for 
example, retinoic acid and BDNF (brain derived neurotrophic 
factor) were added to cultures, and no cell-to-cell contact 
existed in this co-culture system, it appears that membrane 
permeable endogenous factor( s) were released from differen-
tiating NSCs and altered the cell fate decisions of BrdU-
treated MeSCs in a manner not possible with non-treated 
MeSCs. That is, BrdU-treated MeSCs acted as more devel-
opmentally potent cells, in this case like NSCs, which are 
capable of responding to neural environmental cues. 
MeSCs culture: Though they can be isolated utilizing 
numerous methods well known in the are, for the present 
examples, human MeSCs were purchased (Bio Whittaker, 
Walkersville, Md.) and selected by negative selection for 
CD 11 b, CD33, CD34, and CD 133 antigens. The MeSCs were 
cultured in, for example, 20 ml of serum-supplemented 
growth medium consisting of Dulbecco's Modified Eagle 
Medium (Gibco, BRL, Burlington, ON); antibiotic-antimy-
cotic mixture (Gibco); and FBS MesenCult Medium (Stem 
Cell Technologies, Vancouver, BC). The cells were incubated 
at 3 7° C. in a 5% C02 humidified incubation chamber (Fisher, 
Pittsburgh, Pa.). The cells were fed by replacing half the 
culture media twice per week. After 60 passages, the cells 
were still negative for the above-listed antigens. Before in 
vitro and in vivo differentiation, human MeSCs were treated 
with different doses (10 nM-100 µM) of 5-bromo-2-deox-
yuridine (BrdU, Sigma) for various durations (24-240 hr). To 
investigate whether DNA methylation is involved in the BrdU 
effect, cells were treated with BrdU in the presence of 5-aza-
cytidine (0.3-1 mM). The preceding growth conditions are 
applicable to cell types other than MeSCs, such as, for 
example, NSCs and other stem cells. 
Co-cultures of human MeSCs and NSCs: Human NSCs 
(about lxl04 to lxl05 ) were differentiated in serum-free 
basal medium Eagle (BME, Gibco), which contains Earle's 
salt and L-glutamine for five days in a 12-well culture plate 
before co-culture in the absence of FGF-2 and EGF and 
without the addition of other extrinsic differentiation factors. 
Under these condition, NSCs spontaneously differentiated 
into neurons and glia. For the co-culture experiments, BrdU-
treated human MeSCs (about lxl04 to lxl05 ) were trans-
ferred into cell culture inserts with a pore size of 0.4 µm 
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(Falcon, Franklin Lakes, N.J.) and suspended in the basal 
medium over these differentiating NSCs. The ratio ofMeSCs 
40 
to NSCs was approximately 1:1. For immunocytochemical 
analysis of MeSCs, the culture insert was removed from the 
well after seven days of co-culture and the MeSCs were fixed 5 
with methanol for 30 min at -20° C. 
astrocyte staining for GFAP was observed in the CA2 subfield 
of hippocampus. MeSCs-derived cells, with BrdU-labeled 
nuclei, also were localized to areas undergoing active post-
natal neurogenesis, including the Islands of Calleja in the 
ventral forebrain and the subependyma of the olfactory bulb. 
Without the BrdU-treatment, MeSCs transplanted in an 
animal's brain do not exhibit immunoreactivity for the human 
bIII-tubulin and human neurofilament, indicating that BrdU-
treatment is necessary for differentiation of MeSCs even 
10 though environmental cues also contribute to the induction of 
neuronal differentiation of the MeSCs. 
Immunocytochemistry: After fixation, MeSCs were briefly 
washed three times in PBS, then blocked with 3% donkey 
normal serum in PBS containing 0.05% Triton X-100 (PBST) 
for 1 hour and incubated with mouse IgG2b monoclonal 
anti-human bIII-tubulin, clone SDL3D10 (1:500, Sigma) and 
goat anti-human-glial filament protein (GFAP) N-terminal 
human affinity purified (1:200, Research Diagnostics Inc., 
Flander, N.J.) overnight at 4° C. The corresponding second-
ary antibodies were donkey anti-mouse conjugated to 15 
rhodamine and anti-goat IgG (H+L) conjugated to FITC 
(Jackson IR Laboratories, Inc.), respectively. Following a 
brief PBS washing, secondary antibodies were added at a 
These results from in vitro and in vivo tests indicate that 
MeSCs overcome their mesenchymal commitment by substi-
tuted deoxynucleotide or deoxynucleoside treatment and dif-
ferentiate into neural lineage cells that are phenotypically 
unrelated to their embryonic origin. 
Example 4 
1 :200 dilution in PBST for a 2 hr incubation at room tern-
perature (RT) in the dark. The cells were then washed with 20 
PBS and covered with Vectashield with DAPI (Vector Labo-
ratories, Inc., Burlingame, Calif.) for fluorescent microscopic 
observation. 
Migration and Differentiation ofMeSC of the Invention After 
Transplant into Rat Vitreous Cavity 
For transplanting the MeSCs into the vitreous cavity of 
rats, cells were cultured with the long-term maintenance 
media as described above, containing TGF-b3 (1 ng/ml to 10 
micrograms/ml; here 100 ng/ml) and about 2 µM 5-bromo-
2'-deoxyuridine (BrdU) for 3 days in a 6-well tissue culture 
without differentiation before injection. 
Image and data analysis: Digitally-captured images from 
fluorescent microscopy of cultured cells can be analyzed by 25 
NIH Image software (NIH) with Cell Scoring, Particle Analy-
sis, and Cell Analysis macros. The number of cells showing 
particular antibody markers in the areas of interest can be 
counted. In addition, total cell number can be counted by 
DAPI nuclei counterstaining and each cell population will be 30 
expressed as a percentage of the total cell number. The results 
from each treatment condition can be analyzed by ANOVA 
and followed by post-hoc (Fisher's Protected LCD) analysis. 
An injury was intentionally made by a needle while these 
cells were injected to facilitate the migration ofMeSCs. After 
an injury, 20 µl of cell suspension, containing about 1.5xl 05 
to 2x 105 cells, was slowly injected into the intravitreous space 
of the right eye. The left eye was left intact as a control 
without injection. At 30 days post-transplantation, the rats 
Example 3 
Neural Differentiation ofMeSCs of the Invention in Mouse 
Brain 
To test migration and differentiation patterns of BrdU-
treated, more developmentally potent MeSCs in vivo, such 
MeSCs expanded without differentiation as described above 
and labeled by the incorporation of bromodeoxyuridine 
(BrdU) into nuclear DNA were injected into the lateral ven-
tricle of mature mice (C57/black). 
Four to six weeks after transplantation, mouse brains were 
analyzed by immunohistochemistry for human specific bIII-
tubulin and GFAP, markers for neurons and astrocytes respec-
tively. Migration and differentiation patterns of the trans-
planted MeSCs were quite similar to our previous results with 
NSCs transplanted into the rats. The transplanted MeSCs 
with BrdU-immunopositive nuclei differentiated into neu-
rons and astrocytes in the host brain as evidenced by fluores-
cence microscopy after double staining for bIII-tubulin and 
GFAP. MeSC-derived cells are found bilaterally in regions of 
cerebral cortex and hippocampus. The transplanted MeSCs 
migrated over a long distance from the injection site to their 
positional termination. Further analysis with double immun-
ostaining for bIII-tubulin and GFAP revealed that MeSC-
derived neurons and astrocytes were localized in layer V and 
III, respectively, in the cortex (FIGS. 9a,b). These neurons 
were characterized by dendrites pointing to the edge of the 
cortex, and these neuronal dendrites appeared to be associ-
ated with the astrocytes in the layer III of the cortex. Around 
the pyramidal cell layer of the hippocampus (FIGS. 9c-h), 
neurons were immunopositive for bIII-tubulin and exhibited 
morphologies with multiple processes and branches. Strong 
35 were sacrificed and their eyeballs were removed whole. Then 
these eyeballs were paraffin embedded and sliced into 5 µm 
sections. The sections were stained with double-immunof-
luorescent-cytochemistry using rat anti BrdU (1:600, Accu-
rate Chemical & Scientific Corp.) and mouse anti-rhodopsin 
40 (1:200, Chemicon), and mounted on slides, then coverslipped 
using VECTASHIELD mounting medium (Vector) with 
DAPI. 
FIG. 10 show the immunocytochemistry and in situ hybrid-
ization histochemistry (ISHH) of the retinal sections 4 weeks 
45 after transplantation of MeSCs pretreated with BrdU and 
TGF-b3. Extensive migration of these cells into the lesioned 
area of the retina was found (FIG. lOa), similar to other 
researchers, who found migration and incorporation of neural 
stem cells into the retina after intraocular injections (Nishida 
50 eta!., 2000, Invest Ophthalmol Vis Sci 41: 4268-74; Kurimoto 
et al., 2001, Neurosci Lett. 306: 57-60; War:!Vinge et al., 2001, 
Exp. Neural. 169: 1-12). However, for the first time is dem-
onstrated herein that MeSCs incorporated into the photore-
ceptor layer are in fact able to express opsin immunoreactiv-
55 ity (FIG. lOb), in contrast to previous studies that did not 
report such findings (Ibid). Since anti-opsin antibody that 
recognized both human and rat op sin protein was used, it was 
not determined whether opsin is expressed by the donor (hu-
man stem cells) or by the host (rat cells). To overcome this 
60 technical problem, ISHH was conducted as described below 
against the human rhodopsin gene-encoding region. The 
cloned human rhodopsin gene sequence does not recognize 
any other species of opsin genes listed by Genbank: in par-
ticular, this sequence does not show a significant similarity to 
65 any DNA sequence found in rat genes (data not shown). Using 
the human op sin gene sequence as a DIG-labeled RNA probe, 
human opsin expression was detected in the retina following 
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human stem cells transplantation (FIG. lOc). These results 
indicated that MeSCs pretreated with BrdU and TGF-b3 not 
only were incorporated into the rat retina, but they also dif-
ferentiated into photoreceptor cells. MeSCs that were not 
pre-treated with BrdU according to the methods of the inven- 5 
tion were not able to migrate and differentiate in a tissue-
appropriate manner. 
Construction of exemplary human-specific opsin ribo-
probe vectors: A 360 bp fragment of a human-specific 
rhodopsin gene sequence (from 6241 bp to 6601 bp of 10 
U49742) was selected. The selected human rhodopsin gene 
sequence does not have a significant level of homology with 
other rhodopsin genes from other species. In particular, this 
sequence does not show a significant similarity to any DNA 
sequence found in the rat genome (data not shown). The 15 
selected human-specific rhodopsin gene sequence was ampli-
fied from human genome DNA by PCR using a forward 
primer (5'-TTCCCAATGAGGGTGAGATT-3'; SEQ ID NO: 
1) and a reverse primer (5'-GGAATTTCCCACTCTTTGTT-
42 
mM EDTA) for 10 minutes at room temperature and then 
incubated with RNase solution (50 ug/ml of RNase 
(Promega) in RNase buffer) for 30 minutes at 37° C. The 
sections were washed with serial concentration of SSC buffer 
(2x, 0.5x, O.lx) twice for 20 minutes at 60° C., except that the 
last wash was done at RT. After rinsing with PBS, the probe 
was visualized by immunodetection of digoxygenin with a 
primary antibody, sheep anti-digoxigenin (1:500, Roche), 
and secondary antibody with fluorescein (FITC)-conjugated 
AffiniPure donkey anti-sheep IgG (1 :200, Jackson Laborato-
ries). 
Image and data analysis: Digitally-captured images from 
the fluorescent microscopy of cultured cells can be analyzed 
utilizing NIH Image software (NIH) with Cell Scoring, Par-
ticle Analysis, and Cell Analysis macros as described above. 
Example 5 
DNA Methylation and BrdU 
Some DNA restriction digestion enzymes are sensitive to 
cytosine methylation, and they are unable to cut DNA when 
the cutting site includes methylated cytosine. One such 
enzyme (HpaII) was used to investigate whether BrdU treat-
ment altered the enzyme-cutting pattern by modification of 
DNA methylation. Genomic DNA from human MeSCs 
treated with 0 µM, 1 µM and 10 µM BrdU for 72 hr was 
digested and analyzed by polyacrylamide gel electrophoresis 
on 0.6% polyacrylamide gel. In a dose-dependent fashion the 
size of the DNA fragments produced by digestion increased, 
3'; SEQ ID NO: 2). PCR amplification was conducted in 50 µl 20 
volumes containing control human genomic DNA (100 ng, 
Invitrogen), 133 amplification buffer (Invitrogen), 40 nM of 
each primer, dNTP Mix (250 µM, Invitrogen) and Taq DNA 
Polymerase (2.5U, Invitrogen), under conditions of: 95° C. 
(30 seconds), 52° C. (30 seconds), and 72° C. (60 seconds) for 25 
30 cycles. The PCR-amplified fragment was ligated into a 
TOPO TA cloning in vitro transcription vector (Invitrogen) 
after gel purification on 2% agar gel. The plasmid was trans-
formed into E. coli-competent cells (Strategene) and the 
clone was confirmed by sequencing the insert. 30 indicating that BrdU prevented enzyme digestion (FIG. 11). 
This result may be explained by the alteration of DNA methy-
lation status in MeSC by the BrdU treatment. Other substi-
tuted deoxynucleotide or deoxynucleoside compounds are 
suitable replacements for BrdU. 
Example 6 
In situ hybridization histochemistry for human opsin 
mRNA in paraffin embedded sections: Digoxigenin-labeled 
human opsin-specific riboprobes are made by in vitro tran-
scription. Reactions (20 µl) were performed in a reaction 
mixture containing 4 µl of 5xtranscription buffer (USB Cor- 35 
poration), 2 µl of lOxdigoxigenin RNA-labeling mix (0.2 
µg/ml, Roche), 1 µl of template DNA (PCR reaction 
described above, 100 ng/µl), 2 µl of T7 RNA polymerase 
(5U/µl, USB), and 11 µl of molecular biology grade water. 
After mixing with a pipette, the reaction mixture was incu-
bated at room temperature for 2 hours. The pro be was purified 
Transplantation of More Developmentally Potent Cells of the 
Invention to Nucleus Basalis Magnocellularis (NBM) Lesion 
40 RatModel 
by ethanol precipitation and dissolved in 100 µl molecular 
biology-grade water. 10 µl ofthis probe solution was used to 
make the hybridization mixture. Rat eye sections were depar-
affinized with xylene (Fisher) for 5 minutes at room tempera- 45 
ture, and rehydrated using a serial concentration of ethanol 
(Fisher) and distilled water at room temperature. The sections 
were then washed with 0.1 M phosphate-buffered saline 
(PBS), pH 7.4, for 15 min at room temperature followed by 
incubation with 10 ng/ml of proteinase K (Sigma) for 30 50 
minutes at 37° C. The sections were washed twice in glycine 
solution (0.75 g glycine/100 ml of0.1 M PB, pH 7.4) for 5 
minutes at room temperature and treated with 13% triethano-
lamine solution (pH 8.0) containing 2.5% acetic anhydride 
for 10 minutes at room temperature. The sections were then 55 
prehybridized with hybridization buffer after 2 washes with 
2xSSC (saline-sodium citrate buffer, Sigma, pH 7.0) for 15 
minutes each at room temperature (RT). Hybridization buffer 
consists of 50% formamide, lxDenhardt's solution, 10% 
dextran sulfate (Invitrogen), 4xSSC, 0.25 mg/ml yeast tRNA, 60 
and 0.3 mg/ml herring sperm DNA. Hybridization was done 
in the hybridization buffer containing 10 µl of digoxygenin 
riboprobe as described above for 18 hours at 60° C. After 
hybridization, the sections were washed twice with 4xSSC 
buffer, followed by a stringency wash with 50% formamide 65 
and 2xSSC for 30 minutes at 60° C. The sections were washed 
twice with RNase buffer (10 mM Tris, pH 8.0, 0.5 M NaCl, 1 
Stem cell transplantation strategies are advocated inAlzhe-
imer' s disease (AD) neuroregeneration therapy. Basal cho-
linergic neurons, which are selectively degenerated in AD, 
extend long projections into the cortex and hippocampus. An 
open question for neuroreplacement treatment for AD is 
whether these degenerating cholinergic cells can be replaced 
by the transplantation of stem cells. To answer this question, 
more developmentally potent cells of the invention were 
transplanted into nucleus basalis magnocellularis (NBM) 
lesion model rats. The lesions were induced either by an 
injection of ibotenic acid or by anti-NGF receptor antibody 
conjugated with saporin (Advanced Targeting System, San 
Diego, Calif.). Cells prepared according to the invention were 
simultaneously injected into the contralateral side of the lat-
eral ventricle (Qu, 2001) of the NBM-lesioned animal. Four 
weeks after the surgery, the brain was examined by immuno-
histochemistry. Many GFAP-positive cells were detected in 
the lesioned area, but they were not BrdU-positive, indicating 
astrocytes activation in this area. BrdU-positive cells with 
ChAT or bIII-tubulin immunoreactivity were found in the 
lesion site, indicating that more developmentally potent cells 
of the invention migrated from the contralateral ventricle to 
the lesion site and had differentiated into cholinergic and 
other neuronal cells. These neuronally differentiating cells 
were neurons that appeared rather morphologically prema-
ture. Our results indicate a positive study of neuroreplace-
ment treatment for cholinergic neurons in AD. 
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Transplantation of cells of the invention: Male SD rats 
were deeply anesthetized with sodium pentobarbital (50 
mg/kg, i.p.). Using bregma as a reference point, about lxl05 
cells of the invention were collected and slowly injected into 
the right lateral ventricle(AP 1.4; ML3.3; and DY 4.5mm)of 
the rat brain using a stereotaxic apparatus (Devid Kopff). 
Cholinergic lesions induced by 192-IgG-saporin conju-
gate: Male Sprague-Dawley rats, 4-months-old, were anes-
thetized with 50 mg/kg pentobarbital and mounted in a ster- 10 
eotaxic apparatus (David Kopf). Unilateral NBM injections 
of the 1 µg/2 µ1192-IgG-saporin conjugate toxin (ina vehicle 
44 
lesion appears to attract the cells of the invention, indicating 
a possible release of the migration factor(s) from the lesion 
site. 
Example 7 
Expression ofReelin, Alpha 3-Integrin, and DAB-1 in Stem 
Cells 
To investigate the function of reelin in cell culture, human 
MNSCs were differentiated under serum-free conditions. 
Previously, human MNSCs were observed not only survive at 
least three weeks in serum-free conditions, but to fully dif-
ferentiate into b3-tubulin, GFAP, and 04 immunopositive 
cells. 
of sterile filtered 200 mM phosphate buffer (pH 7.4)) were 
performed using a microsyringe. The NBM was stereotaxi-
cally localized using the following coordinates: AP=-2.3 mm 15 
from bregma, ML=±3.7 mm, 7.5 mm below dura. The toxin 
was delivered over 5 minutes and the needle was left in place 
for another 5 minutes following injection. 
Immunohistochemistry: Rats were sacrificed by an over-
dose of anesthesia (sodium pentobarbital, 70 mg/kg, i.p.) and 
perfused with phosphate buffered saline (PBS) followed by 
4% paraformaldehyde. Brains were removed and placed into 
the 4% paraformaldehyde fixative containing 20% sucrose 
for overnight. The brains were sliced into 20 µm, coronal 
25 
sections using cryomicrotome. The sections were washed 
briefly in PBS and pretreated with 1 M HCL for 30 minutes at 
room temperature (RT) and neutralized with sodium borate 
Reelin may serve to regulate migration based on the finding 
that exposure to recombinant reelin causes the differentiating 
human MNSCs cultures to immediately retract their pro-
20 cesses back to the cell cluster. The cell cluster is composed of 
undifferentiated cultured cells with migrating and differenti-
ating cells forming the leading outer processes. 
To assess the presence of reelin and responsive mecha-
nisms in HNSCs, immunocytochemistry and Western blot 
analysis were performed using antibodies recognizing reelin 
alpha 3-integrins (a3-integrins) and DAB-1. Five days after 
differentiation, reelin immunoreactivity (green) was present 
mainly on small bipolar cells suggestive of neurons, and very 
little reelin immunoreactivity was detected in GFAP positive 
cells (red), which are suggestive of astrocytes (FIG. 16a). 
a3-integrin immunoreactivity was also detected in small 
bipolar cells but not in GFAP-positive cells, indicating 
expression of a3 integrin predominant in neurons (FIG. l 6b ), 
while in DAB-1, a cytoplasmic adapter protein, immunore-
activity was detected in not only neurons but also in astrocytes 
(FIG. 16c ). Intracellular distribution ofDAB-1 was higher in 
the nucleus and was evenly distributed in the cytoplasm. 
Using the electron microscope, a3-integrin immunoreactivity 
(O. lM, pH 8.0) for 30 minutes, in order to increase the acces-
sibility of the anti-BrdU antibody to the BrdU incorporated in 30 
the cell nuclei. After rinsing with PBS, sections were trans-
ferred to a solution containing 0.25% Triton X-100 in PBS 
(PBST) for 30 minutes. Then the sections are blocked in 
PBST containing 3% donkey normal serum for 1 hr and 
incubated in mouse anti-BrdU (1:200DSHB, Iowa City, 35 
Iowa) or sheep anti-BrdU (l:lOOOJackson IR Laboratories, 
Inc. West Grove, Pa.) diluted in PBST overnight at 4° C. 
Sections were then washed with PBS and incubated with 
mouse IgG2b monoclonal anti-human bIII-tubulin, clone 
SDL3D10 (1:500, Sigma), rat IgG monoclonal anti-ChAT 
(1:500, Boehringer-Mannheim) and goat anti-human-glial 
filament protein, N-terminal human affinity purified (1:200, 
Research Diagnostics Inc., Flander, N.J.), respectively, for 
overnight at 4 ° C. in the dark. After rinsing in PBS, donkey 
anti-mouse, donkey anti-rat, donkey anti-goat or donkey anti-
sheep IgG conjugated with rhodamine or FITC (Jackson IR 
Laboratories, Inc.) were added at 1 :200 dilution in PBST for 
40 was observed to be localized on the cell membranes (FIG. 
17). In FIG. 16, reelin appears to have been released from 
reelin-positive cells and to have reached neighboring cells. 
Western blot analysis of samples prepared by immunopre-
cipitation from differentiated HNSCs with monoclonal anti-
45 body (Reelin 142) showed reelin, a3 integrin, and DAB-1 
immunopositive bands (FIG. 18), indicating that these mol-
ecules interact with each other in the reelin signaling cascade, 
and that reelin released from a population of cells may coor-
dinate movement of these cells as a regulator of stem cell 
2 hours at RT in the dark. Sections were then washed with 
PBS thoroughly before mounting on glass glides. The sec-
tions were coverslipped with mounting media containing 
DAPI for nucleus counter staining. 
Increased GFAP immunoreactivity in the NBM was 
observed 4 weeks after saporin lesion. (FIG. 12. Green: 
GFAP; Blue: DAPI). Choline acetyltransferase (ChAT) 
immunoreactivity was also observed in BrdU positive cells in 
the lesion site (FIGS. 13a-c. Green: ChAT; Red: BrdU; Blue: 
DAPI), indicating replacement oflesioned cells by the trans-
planted cells of the invention. Further, ChAT immunoreactiv-
ity was observed n human nuclei positive cells in the lesion 
site. (FIG. 13d. Green: ChAT; Red: human nuclei; Blue: 
DAPI). Human nuclei immunoreactivity-positive cells were 
observed in the lesion area (FIG. 14. Red: human nuclei; 
Blue: DAPI) and GFAP and human nuclei immunoreactivity 
were observed in the lesion site. (FIG. 15. Green: GFAP; Red: 
human nuclei; Blue: DAPI). A large number of transplanted 
cells migrated to the lesion site and differentiated into rather 
mature neurons and glia 4 weeks after transplantation. The 
50 biology. 
Since reelin immunoreactivity was also present in the cell 
cluster before differentiation (FIG. 17d), it is possible that 
HNSC movement is organized by the active production of 
55 reelin within the center of the cluster, which may also serve to 
prevent a rapid state of differentiation. The cells located on 
the outer edge of the cluster, on the other hand, may be 
exposed to lower concentrations of reelin. Consequently, 
these cells are less restricted and begin to differentiate and 
60 migrate out from the center of the cluster. Since undifferen-
tiated stem cells express reelin, reelin expression was also 
investigated in mouse embryonic stem cells. A subpopulation 
of embryonic stem cells in three days old embryos expressed 
reelin, indicating that reelin is a factor that regulates stem cell 
65 biology because it is expressed in embryonic stem cells 
before Cajal-Retzius cells begin to produce reelin during 
corticogenesis. 
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Example 8 
Transplantation of Stem Cells to Reeler Mice . . . 
The effects of reelin on the migratory and d1fferentrnt10n 
5 pattern of human MNSCs in vivo were investigated. Hu~an 
MNSCs were expanded without differentiation as descnbed 
above and treated by the incorporation of BrdU into nuclear 
DNA. Then, human MNSCs were injected in to the lateral 
ventricle of wild ( c57 /black) and reeler mice at one month 
10 
old. Brain from these animals were investigated by immuno-
histochemistry for bIII-tubulin, GFAP, and BrdU four weeks 
after injection. Wild-type animals showed diff~re~tiation and 
distribution patterns of transplanted FINSCs s1m1lar to those 
found in previous rats transplantation studies (FIG. 20). 
15 Human MNSCs transplanted in reeler mice did not suc-
cessfully migrate into the host brain. In the cortex, a few 
GFAP-positive cells were detected (FIG. 21d), but bIII-tub1;1-
lin positive HNSCs were not present (FIG .. 2~a ) .. bIII-_tubu~m 
positive human MNSCs found near the mJect10n site dis-
20 played an unusual morphology (FIG. 21b). Reelin p~sitive 
human MNSCs showed a trained migration pattern m the 
white matter of the cortex (FIG. 21.1), indicating that environ-
mental reelin is necessary for the migration ofNSCs and that 
the cells expressing reelin have potential to migrate in reeler 
25 
mice. 
Example 9 
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type of shrunken morphology that cells undergoing apoptotic 
cell death display. To further assess the type of cell death, a 
TUNEL assay was used to detect in situ DNA fragmentation, 
an early marker of apoptosis, in HNSCs different!~ted in 
serum or in serum-free media. Many cells were positive for 
the TUNEL signal under serum-free differentiation condi-
tions and displayed soma! shrinkage followed by cell detach-
ment from the culture plates. In contrast, only a few TUNEL-
positive cells were detected under serum differentiation 
conditions (FIG. 24). Since neurons are known to undergo 
apoptosis after serum deprivation, and B27 is reported ~o 
prevent neuronal death in cultured cortical .tis.sue, apo~t.os1s 
of human MNSCs in serum-free differentrnt10n cond1t10ns 
may be due to supplement deprivation. Our time lapse video 
microscopic study of human MNSCs plated in ~erum-~ree 
unsupplemented media for 1 DIV revealed that d1fferentrnt-
ing human MNSCs appear to reach out to the nearby mor-
phologically apoptotic cells described.a~~ve (FIG. 25). These 
results suggest that human MNSCs 1mtrnlly become apop-
totic under serum-free differentiation conditions and subse-
quently express migration and/or differentiation factors to 
influence the fate of neighboring cells. 
A combination of immunocytochemistry with 22Cl 1, 
which is a monoclonal antibody recognizing the N-terminal 
end of APP and the TUNEL assay revealed a marked increase 
of APP immunoreactivity in the TUNEL-signal-positive cells 
Analysis of Stem Cell Populations in Reeler Mice 
Since the examples described herein indicate poor stem 
cells migration patterns in reeler mice, we suspect~d a sii:iiiar 
migration pattern for endogenous stem cells. To mvestJgate 
the endogenous stem cell population in reeler mice co.mpared 
with the wild-type mice, BrdU (100 mg/kg/day) was mJected 35 
into reeler homozygous, reeler heterozygous, and wild-type 
mice for four days. The hippocampus and SVZ of these mice 
were immunofluorescent stained for BrdU. Mouse NSCs, 
which proliferated during the injection period, incorporate.d 
BrdU into their nuclei, which can be detected as BrdU pos1- 40 
tive cells. Significantly reduced BrdU positive cells were 
found in the hippocampus of both reeler homozygous and 
heterozygous mice compared with wild-type mice (FIG. 22), 
while stem cell populations in SVZ of reeler homozygous and 
heterozygous mice were preserved (FIG. 22), indicating. that 45 
the proliferation of stem cells was not affected, but the m1gr~­
tion of the stem cells from SVZ to hippocampus was dramati-
cally diminished by the lack ofreelin. 
under serum-free differentiation conditions compared to the 
background levels of APP found in neighboring hu~an 
MNSCs (FIG. 26). This result not only confirms p~ev10us 
30 findings that APP expression is elevated in the apoptot1c cell.s, 
but more importantly suggests that one factor produced m 
apoptotic cells to influence the differentiation of neighboring 
cells could be the N-terminal fragment of APP. 
Example 10 
Isolation of Stem Cells from the Reeler Mice 
Example 12 
Inhibition of Human MNSC Differentiation under Non-Se-
rum Conditions by an Antibody Against APP 
To investigate the involvement of the secreted APP frag-
ment during differentiation, HNSCs were co-incubated in 
serum or serum-free differentiation conditions for three days 
with various 22Cl 1 concentrations. The addition of22Cl 1 to 
the culture dose-dependently (125, 250, 500 µg/ml) inhibited 
differentiation of human MNSCs under serum-free unsupple-
mented conditions (FIG. 27). In contrast, 22Cl 1 treatment 
did not inhibit the differentiation of human MNSCs under 
serum differentiation conditions (data not shown). These 
results suggest that APP is involved in the differentiation of 
human MNSCs under serum-free differentiation conditions 
50 
while differentiation factors independent of the APP pathway 
exist under serum differentiation conditions. 
NSCs were isolated from adult mice ( 4 months old, C57 I 
black) as responders for bFGF. They were expanded in vitro 
55 
using the same media as used for human MNSC cultures. The 
cells formed clusters (FIG. 23a), which are similar to the ones 
formed by the NSCs. These NSCs were capable of producing 
neurons and astrocytes by differentiation after three months 
Example 13 
Treatment of HNSCs with Secreted-Type APP 
To investigate whether 22Cl 1-induced inhibition of 
human MNSC differentiation occurs through the sequester-
ing of sAPP or by blocking the N-terminal domain of APP on 
of in-vitro expansion (FIG. 23b ). 
Example 11 
Characteristics of Differentiated Human MNSCs under Non-
Serum Condition 
During the early stages (1-3 days in vitro, DIV) of serum-
free differentiation, many human MNSCs exhibited the same 
60 the membrane of differentiating cells, human MNSCs were 
treated with exogenous sAPP. Recombinant human sAPP was 
produced in yeast, which contains 95% sAPP695T ( e~~ing at 
amino acid 505 of 695) and 5% sAPP695. The add1t10n of 
recombinant sAPP to the cell culture media dose-dependently 
65 (25, 50 and 100 ng/ml) differentiated human MNS~s (FIG. 
28) under serum-free differentiation conditions. This result 
suggests that the sequestering of sAPP by 22Cl 1 may play a 
US 7,635,467 B2 
47 
role in inhibiting HNSC differentiation. sAPP treatment did 
not increase the TUNEL signal in human MNSCs (data not 
shown). 
The cell population of sAPP-treated human MNSCs at 5 
DIV under the serum-free differentiation condition was also 5 
48 
described above. Cells distributed bilaterally in the singular 
and parietal cortexes (layer II, IV and V) (FIG. 32a) and 
hippocampus (pyramidal cell layer) (FIG. 35c) were 
intensely and extensively immunopositive for BrdU and 
human bIII-tubulin. The transplanted human MNSCs also 
differentiated into GFAP-immunopositive cells that co-local-
ized with the neuronal fibers of layer III in the cortex (FIG. 
32e). These morphologies and distributions ofbIII-tubulin-
or GFAP-positive cells were not detected in wild-type control 
10 mice that did not receive human MNSC transplantation. 
characterized by double immunofluorescence labeling of 
GFAP and bIII tubulin (FIG. 29). Treatment with sAPP dose 
dependently (25, 50, 100 ng/ml) increased the population of 
GFAP positive cells from an average of 45% in controls (no 
sAPP) to an average of83% using the highest concentration 
ofsAPP (lOOng/ml at 5 DIV). Higher doses ofsAPP (50 and 
100 ng/ml) dose-dependently decreased bIII-tubulin-positive 
neurons in the total population of differentiated human 
MNSCs, from an average of 51 % in controls to an average of 
13% in the highest concentration of sAPP (FIG. 30). These 15 
results indicate that sAPP released from dying cells promotes 
differentiation of human MNSCs while causing gliogenesis 
Although human MNSCs transplanted into the APP knock-
out mice also differentiated into bIII-tubulin and GFAP-posi-
tive cells, distribution and migration patterns were not sym-
metric and the number of the differentiated cells was lower 
than in compared to control wild-type mice. Despite the 
rather uniform bIII-tubulin positive cell distribution and 
structure in the hippocampus of APP knockout mice (FIGS. 
32dj), bIII tubulin positive HNSCs were scarcely distributed 
in the cortex and lacked apical dendrites (FIG. 3 2b). Although 
it is conceivable that the APP expression of transplanted 
human MNSCs may partially compensate for the APP deficit 
in the host brain, it is quite apparent that such levels of 
expression are negligible and that the absence of environmen-
tal APP clearly alters the migration pattern of transplanted 
at higher doses. sAPP can influence the cell fate decision of 
human MNSCs by increasing glial differentiation; sAPP may 
cause an accelerated migration of astrocytes resulting in 20 
increased levels of glial cell differentiation; and high concen-
trations of sAPP may reduce or eliminate the human MNSC 
population differentiating into neurons, since high APP 
expression in neuronal cell lines have been reported to cause 
apoptotic cell death by caspase 3 activation. 25 HNSCs. These results indicate that there were insufficient 
Example 14 
Effect of APP Transgene to Human MNSCs 
To confirm the glial differentiation promoting effect of 30 
sAPP, human MNSCs were transfected with manmialian 
expression vectors containing genes for either wild-type APP 
or sAPP and differentiated under serum-free unsupplemented 
conditions. Human MNSCs transfected with wild-type APP 
revealed a significantly higher level of glial differentiation 35 
compared with human MNSCs transfected with the vector 
alone at 5DIV (FIG. 31). These results indicate that in addi-
tion to the excess of sAPP, wild-type APP over-expression 
can also induce glial differentiation of HNSCs. This finding 
may have relevance in Down Syndrome (DS), a chromosomal 40 
abnormality resulting in trisomy 21. In addition to its charac-
teristic physical manifestations, DS patients often exhibit 
early-onset AD. Since the APP gene is also located on chro-
mosome 21, the increase of APP gene expression by trisomy 
21 may explain the excess amount of APP in the brain. It has 45 
been suggested that APP plays a role in neuronal development 
and that the earlier appearance of AD in adult DS patients is 
associated with an abnormal regeneration process related to 
environmental factors to properly guide the migration and 
differentiation of HNSCs in APP knockout mice, and that 
environmental or secreted APP may be important factors in 
regulating cell fate and migration of human MNSCs in vivo. 
Example 16 
Analysis of Stem Cell Populations in APP Knockout Mice 
Since the results set forth above indicated inadequate stem 
cells migration patterns in APP knockout mice, a similar 
migration pattern was expected for endogenous stem cells. To 
investigate this, the endogenous stem cell population in APP 
mice were compared with wild-type mice. BrdU (100 mg/kg/ 
day) was injected into APP knockout and wild-type mice for 
four days. The hippocampus and SVZ of the test mice were 
immunofluorescently stained for BrdU. Mouse NSCs, which 
proliferated during the injection period, incorporated BrdU 
into their nuclei, which can be immunofluorescently detected. 
BrdU-positive cells in the hippocampus of APP knockout 
mice were reduced compared with wild-type mice (FIG. 33); 
whereas, stem cell populations in SVZ of APP knockout mice 
aging. 
were preserved (FIG. 33), indicating that the proliferation of 
stem cells was not affected, but the migration of stem cells 
from SVZ to the hippocampus was decreased by the lack of 
50 APP. 
Example 15 
Transplantation of HNSCs to APP Knockout Mice 
The regulatory effect of APP on human MNSCs biology in 
vivo was further investigated by transplanting HNSCs into 
the brains of APP knockout mice. 
To differentiate between host and transplanted cells, 
human MNSCs were labeled in vitro by the incorporation of 
bromodeoxyuridine (BrdU) into the DNA before transplan-
tation. These labeled cells (about 105 ) were subsequently 
injected unilaterally into the cerebral lateral ventricle of c57 I 
black wild-type and APP knockout mice at 2 months of age. 
Immunohistochemical examination of wild-type brain sec-
tions four weeks after transplantation revealed migration and 
differentiation patterns similar to the previous study with 
human MNSC transplantation to aged, memory-impaired rats 
It should be understood that the foregoing disclosure 
emphasizes certain specific embodiments of the invention 
and that all modifications or alternatives equivalent thereto 
are within the spirit and scope of the invention as set forth in 
55 the appended claims. 
We claim: 
1. Developmentally potent mesenchymal stem cells pre-
pared according to a method comprising contacting mesen-
60 chymal stem cells with an effective amount of substituted 
deoxynucleotide or deoxynucleoside for an effective period, 
further comprising the step of co-culturing the mesenchymal 
stem cells contacted with substituted deoxynucleotide or 
deoxynucleoside with neural-lineage cells or media condi-
65 tioned with neural-lineage cells, wherein the substituted 
deoxynucleotide or deoxynucleoside-contacted, mesenchy-
mal stem cells become developmentally potent mesenchymal 
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stem cells capable of differentiating to cells of neural lineage, 
with or without further comprising the step of contacting the 
mesenchymal stem cells with heparin, a growth factor or 
substituted deoxynucleotide or deoxynucleoside in an 
uncoated flask or a flask that has been treated to repel the cells, 
and wherein the substituted deoxynucleotide or deoxy-
nucleoside is bromodeoxyuridine, bromodeoxycytidine, bro-
modeoxyguanosine, methyldeoxythymidine, or chlorodeox-
yuridine. 
2. Developmentally potent mesenchymal stem cells of 
claim 1, wherein the cells form a cluster of two or more cells. 
3. Developmentally potent mesenchymal stem cells of 
claim 2, wherein the cluster of cells comprise less than about 
50 percent redifferentiated cells. 
4. Developmentally potent mesenchymal stem cells of 
claim 2, wherein the cluster of cells comprise less than about 
25 percent redifferentiated cells. 
5. Developmentally potent mesenchymal stem cells of 
claim 2, wherein the cluster of cells comprise less than about 
10 percent redifferentiated cells. 
6. Developmentally potent mesenchymal stem cells of 
claim 2, wherein the cluster of cells comprise less than about 
5 percent redifferentiated cells. 
7. Developmentally potent mesenchymal stem cells of 
claim 2, wherein the cluster of cells comprise less than about 
1 percent redifferentiated cells. 
8. A pharmaceutical composition comprising a pharma-
ceutically-acceptable carrier or excipient and developmen-
tally potent mesenchymal stem cells prepared according to 
the methods of claim 1. 
9. A cellular preparation comprising, as an active ingredi-
ent, developmentally potent mesenchymal stem cells of claim 
1, 2, 3, 4, 5, 6 or 7. 
50 
chymal stem cells with an effective amount of substituted 
deoxynucleotide or deoxynucleoside for at least three days, 
wherein the substituted deoxynucleotide or deoxynucleo-
side-contacted, mesenchymal stem cells become develop-
mentally potent mesenchymal stem cells capable of differen-
tiating to cells of neural lineage, with or without further 
comprising the step of contacting the mesenchymal stem cell 
with heparin, a growth factor or substituted deoxynucleotide 
or deoxynucleoside in an uncoated flask or a flask that has 
10 been treated to repel the cells, and wherein the substituted 
deoxynucleotide or deoxynucleoside is bromodeoxyuridine, 
bromodeoxycytidine, bromodeoxyguanosine, methyldeox-
ythymidine, or chlorodeoxyuridine. 
16. Developmentally potent mesenchymal stem cells of 
15 claim 15, wherein the cells form a cluster of two or more cells. 
17. Developmentally potent mesenchymal stem cells of 
claim 16, wherein the cluster of cells comprise less than about 
50 percent redifferentiated cells. 
18. Developmentally potent mesenchymal stem cells of 
20 
claim 16, wherein the cluster of cells comprise less than about 
25 percent redifferentiated cells. 
19. Developmentally potent mesenchymal stem cells of 
claim 16, wherein the cluster of cells comprise less than about 
25 10 percent redifferentiated cells. 
20. Developmentally potent mesenchymal stem cells of 
claim 16, wherein the cluster of cells comprise less than about 
5 percent redifferentiated cells. 
21. Developmentally potent mesenchymal stem cells of 
30 claim 16, wherein the cluster of cells comprise less than about 
1 percent redifferentiated cells. 
10. A pharmaceutical composition comprising develop-
mentally potent mesenchymal stem cells of claim 1, 2, 3, 4, 5, 35 
6 or7. 
22. A pharmaceutical composition comprising a pharma-
ceutically-acceptable carrier or excipient and developmen-
tally potent mesenchymal stem cells of claim 15. 
23. A cellular preparation comprising, as an active ingre-
dient, developmentally potent mesenchymal stem cells of any 
one of claim 15, 16, 17, 18, 19, 20, or 21. 11. The pharmaceutical composition according to claim 10 
further comprising a pharmaceutically acceptable carrier. 
12. A cell having a second developmental potential pheno-
type prepared according to a method comprising the steps of: 40 
24. A pharmaceutical composition comprising develop-
mentally potent mesenchymal stem cells of any one of claim 
15, 16, 17,18,19,20,or21. 
a) contacting a cell of a first developmental potential phe-
notype with an effective amount of substituted deoxy-
nucleotide or deoxynucleoside for an effective period 
that causes the cell to change into a second developmen-
25. The pharmaceutical composition according to claim 24 
further comprising a pharmaceutically acceptable carrier. 
tal potential phenotype distinct from the first develop- 45 
mental potential phenotype; and 
26. A method for making developmentally potent mesen-
chymal stem cells capable of differentiating to cells of neural 
linage, the method comprising the steps of contacting mes-
enchymal stem cells with an effective amount of substituted 
deoxynucleotide or deoxynucleoside for an effective period; 
and co-culturing the mesenchymal stem cells contacted with 
b) co-culturing the substituted deoxynucleotide or deoxy-
nucleoside-contacted cell of a) with neural-lineage cells 
or media conditioned with neural-lineage cells, 
wherein the first developmental potential phenotype is a 50 
less developmentally potent mesenchymal stem cell; 
substituted deoxynucleotide or deoxynucleoside with neural-
lineage cells or media conditioned with neural-lineage cells, 
wherein the substituted deoxynucleotide or deoxynucleo-
side-contacted, mesenchymal stem cells become develop-
mentally potent mesenchymal stem cells capable of differen-
wherein said second developmental potential phenotype is 
a more developmentally potent mesenchymal stem cell 
capable of differentiating into a cell of neural lineage; 
and 
wherein the substituted deoxynucleotide or deoxynucleo-
side is bromodeoxyuridine, bromodeoxycytidine, bro-
modeoxyguanosine, methyldeoxythymidine or chloro-
deoxyuridine. 
13. The developmentally potent mesenchymal stem cells 
of any one of claim 1, 2, 3, 4, 5, 6 or 7 wherein the substituted 
deoxynucleotide or deoxynucleoside is bromodeoxyuridine. 
14. The cell having a second developmental potential phe-
notype of claim 12 wherein the substituted deoxynucleotide 
or deoxynucleoside is bromodeoxyuridine. 
15. Developmentally potent mesenchymal stem cells pre-
pared according to a method comprising contacting mesen-
55 tiating to cells of neural lineage, with or without further 
comprising the step of contacting the mesenchymal stem cells 
with heparin, a growth factor or substituted deoxynucleotide 
or deoxynucleoside in an uncoated flask or a flask that has 
been treated to repel the cells, and wherein the substituted 
60 deoxynucleotide or deoxynucleoside is bromodeoxyuridine, 
bromodeoxycytidine, bromodeoxyguanosine, methyldeox-
ythymidine, or chlorodeoxyuridine. 
27. The method of claim 26 wherein the developmentally 
potent mesenchymal stem cells form a cluster of two or more 
65 cells. 
28. The method of claim 26 further comprising contacting 
the mesenchymal stem cells with a growth factor. 
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29. The method of claim 28 wherein the growth factor is 
fibroblast growth factor, epidermal growth factor or a combi-
nation thereof. 
30. The method of claim 28 wherein the growth factor is 
fibroblast growth factor or epidermal growth factor. 
31. The method of claim 28 wherein the growth factor is 
fibroblast growth factor. 
32. The method of claim 28 wherein the growth factor is 
epidermal growth factor. 
33. The method of claim 26 further comprising the step of 10 
contacting the mesenchymal stem cells with heparin. 
34. The method of claim 26 wherein the mesenchymal 
stem cells are obtained from a zygote, blastocyst, embryo, 
fetus, infant juvenile or adult. 
35. The method of claim 26 wherein the mesenchymal 15 
stem cells are obtained from a human. 
36. A method for changing a developmental potential phe-
notype of mesenshymal stem cells, comprising the steps of 
contacting mesenchymal stem cells of a first developmental 
potential phenotype with an effective amount of substituted 20 
deoxynucleotide or deoxynucleoside for an effective period 
that causes the mesenchymal stem cells to change into a 
second developmental potential phenotype distinct from the 
first developmental potential phenotype; and co-culturing the 
substituted deoxynucleotide or deoxynucleoside contacted 25 
mesenchymal stem cells with neural-lineage cells or media 
conditioned with neural-lineage cells, wherein said second 
developmental potential phenotype is capable of developing 
to cells of neural lineage, and wherein the substituted deoxy-
nucleotide or deoxynucleoside is bromodeoxyuridine, bro- 30 
modeoxycytidine, bromodeoxyguanosine, methyldeoxythy-
midine, or chlorodeoxyuridine. 
37. A method for making developmentally potent mesen-
chymal stem cells capable of differentiating to cells of neural 
Image from mesenchymal stem cells, the method comprising 35 
contacting mesenchymal stem cells with an effective amount 
52 
of substituted deoxynucleotide or deoxynucleoside for at 
least three days, wherein the substituted deoxynucleotide or 
deoxynucleoside-contacted mesenchymal stem cells become 
developmentally potent mesenchymal stem cells capable of 
differentiating to cells of neural lineage, with or without 
further comprising the step of contacting the mesenchymal 
stem cell with heparin, a growth factor or substituted deoxy-
nucleotide or deoxynucleoside in an uncoated flask or a flask 
that has been treated to repel the cells, and wherein the sub-
stituted deoxynucleotide or deoxynucleoside is bromodeox-
yuridine, bromodeoxycytidine, bromodeoxyguanosine, 
methyldeoxythymidine, or chlorodeoxyuridine. 
38. The method of claim 37 wherein the mesenchymal 
stem cells are contacted with substituted deoxynucleotide or 
deoxynucleoside in an uncoated flask or a flask that has been 
treated to repel the cells. 
39. The method of claim 37 wherein the developmentally 
potent mesenchymal stem cells form a cluster of two or more 
cells. 
40. The method of claim 37 further comprising contacting 
the mesenchymal stem cells with a growth factor. 
41. The method of claim 40 wherein the growth factor is 
fibroblast growth factor, epidermal growth factor or a combi-
nation thereof. 
42. The method of claim 40 wherein the growth factor is 
fibroblast growth factor. 
43. The method of claim 40 wherein the growth factor is 
epidermal growth factor. 
44. The method of claim 37 further comprising the step of 
contacting the mesenchymal stem cells with heparin. 
45. The method of claim 37 wherein the mesenchymal 
stem cells are obtained from a zygote, blastocyst, embryo, 
fetus, infant juvenile or adult. 
46. The method of claim 37 wherein the mesenchymal 
stem cells are obtained from a human. 
* * * * * 
